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The advent of metabolic engineering and synthetic biology has resulted in a 
proliferation of microbial cell factories capable of producing valuable chemical products 
in diverse microbial hosts. This promises to provide a means to produce many of the 
chemical products which are currently derived from petroleum in an alternative, 
environmentally friendly, renewable process. Muconic acid is a chemical of particular 
interest for bioproduction as it can serve as a precursor for many compounds including 
the polymers nylon and polyethylene terephthalate. My initial research resulted in 
importing the biosynthetic capacity for muconic acid into the yeast host Saccharomyces 
cerevisiae.  Through this work, we demonstrated the novel production of muconic acid 
for the first time in yeast and performed subsequent strain engineering to increase titers to 
140mg/L, then the highest titer of any product from the shikimate pathway in yeast [1].   
To further improve muconic acid titers, we chose to use adaptive laboratory 
evolution to complement initial, rational metabolic engineering efforts. To facilitate the 
screening of mutant strains with increased muconic acid production, a transcription-factor 
based biosensor was created.  This biosensor was created to detect aromatic amino acids 
as a surrogate for flux through the shikimate pathway, the precursor pathway also used 
for muconic acid biosynthesis.  This biosensor was based on the Aro80p transcription 
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factor and demonstrated both tunable induction upon aromatic amino acids as well as a 
constitutive mode that created ultra-strong promoters capable of two-fold stronger 
expression that TDH3 (GPD), one of the strongest promoters available in yeast [2].  
Finally, the utility of this biosensor coupled with adaptive laboratory evolution 
was demonstrated in a further approach to increase muconic acid production.  Namely, 
this sensor was used in a biosensor-enabled adaptive laboratory evolution scheme to 
increase titers in our original strain to over 550 mg/L muconic acid in shake flask and 
1.94g/L in a fed-batch bioreactor.  This work represents a 14-fold improvement in titer 
over our previously engineered strain and nearly a 400-fold increase over simple 
heterologous expression of the pathway.  These results demonstrate the power of 
coupling rationale engineering with adaptive engineering to increase product titers.   
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CHAPTERS 
Chapter 1: Introduction and Background 1 
1.1 METABOLIC  ENGINEERING OF MICROBIAL HOSTS FOR CHEMICAL PRODUCTION 
 
 
If the 20th century was the century of physics, the 21st century will be the century of 
biology. While combustion, electricity and nuclear power defined scientific advance in 
the last century, the new biology of genome research—which will provide the complete 
genetic blueprint of a species, including the human species—will define the next.  
-  Craig Venter and Daniel Cohen  [3] 
 
Biology seems poised to create disruptive technologies in the chemical industry. 
Specifically, a wide variety of commodity chemicals have been produced with microbial 
hosts functioning as biocatalysts [4-8].  Moreover, these organisms facilitate the 
production of these molecules from renewable sources. These processes have a number 
of advantages over existing production streams: utilizing diverse and sustainable 
feedstocks, reduced emission of greenhouse gases, reduced toxic or hazardous starting 
materials and/or intermediates, and “green” technology designation. 
While significant efforts have expanded the chemical palate which can be 
produced by these microorganisms [4, 7, 9, 10], complementary work has also gone into 
expanding the range of substrates (including lignocellulosic biomass) in an effort to 
reduce cost and economic viability of these processes [4, 11].  
Microbial hosts have produced a number of important and interesting chemicals.  
Specifically, many common, endogenous, metabolites have been exploited for chemical 
production such as ethanol, citric acid, and lipids [5-7, 12]. Secondary metabolites, such 
                                                 
1 Leavitt, J. M., Alper, H. S., Advances and current limitations in transcript-level control of gene 
expression. Current opinion in biotechnology 2015, 34, 98-104.  The author made significant contributions 
to preparing and editing the manuscript.  
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as terpenoids and other natural products have more recently been explored for microbial 
production[8, 13].  In more recent years, microbial hosts have been explored for the 
production of non-natural products that are often the result of composite pathway 
assembly, as is the case with muconic acid [5, 14, 15].  In these efforts, endogenous 
pathways can be further augmented through the integration of composite pathways from 
heterologous sources facilitating the formation of a diverse range of non-native products 
and removal of endogenous regulation [16, 17]. 
Heterologous expression is not enough in these host systems to create 
industrially-relevant titers and yields.  To address these issues, a number of recently 
developed technologies have been explored to increase metabolic flux.  Traditional 
metabolic engineering is the most-often attempted first step that relies on pathway 
modeling and the rational balancing to produce an optimal carbon flux from feedstock to 
product [18, 19].  Additionally, the development and maturity of systems and synthetic 
biology (aided by ‘omics studies and gene synthesis) has expanded the number of rational 
changes which can be made based on model-based predictions [4, 16, 20].  Finally, 
advances in adaptive laboratory evolution (in ways that have progressed beyond 
traditional strain breeding and classical mutagenesis) have led to a further increase of 
pathways when the target is not known a priori [21-23].  Collectively, genetic 
manipulation such as those described above lead to improved titers, yields, and 
productivity leading to biocatalysts which can then be scaled-up from the bench to 
industrial levels [6].  These central tenants now form the basis of metabolic engineering 
and strain development.  
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1.2 BIOPRODUCTION OF MUCONIC ACID  
Muconic acid, 2,3-hexadienedioic acid, is a unsaturated dicarboxylic acid that has 
sparked interest as a platform compound for chemical production. Muconic acid can 
serve as a precursor for a variety of chemical compounds including terephalic acid, adipic 
acid, and trimellitic acid. These three chemicals are used to synthesize polyethylene 
terephthalate (PET), nylon, trimellitic anhydride, other industrial plastics, food 
ingredients, cosmetics, and pharmaceuticals [15].  PET and nylon alone represent an 
addressable market value of 22 billion a year [24].  
Muconic acid was initially produced in E. coli with continuing development as a 
production platform. Over 20 years, titers were raised 24-fold from 2.4 g/L to 59.2 g/L 
[25, 26]. While E. coli was initially developed as the host for industrial muconic acid 
production, yeast has significant advantages which make it worthy as a production host 
for muconic acid. Yeast has the economic advantages of lower growth temperature, lack 
of phage susceptibilities, less stringent nutritional requirements and the utilization of 
biomass byproducts as animal feeds [8, 10, 27, 28]. The low pH tolerance and ethanol 
production of yeast also represents an advantage for the production of an acidic 
compound which is more soluble in ethanol than water.  
In addition to these benefits, recent work has demonstrated the use of muconic 
acid producing yeast in a hybrid fermentation and electrocatalytic process [24]. In that 
study, fermentation broth from muconic acid producing cultures was electrocatalytically 
hydrogenated to produce a bio-based unsaturated nylon-6,6 without requiring separation, 
significantly improving the economic viability of synthesizing polymer products from 
muconic acid producing yeast strains [24].  
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However, despite advances, titers remain low due to a reduced capacity to divert 
flux from the aromatic amino acid pathway in yeast [29-34].  Specifically, titers and 
yields of shikimate pathway derived molecules in yeast are lower than bacterial 
counterparts.  Thus, additional work is necessary in the field to make yeasts a superior 
host for the production of these molecules.  Moreover, most rational targets for this 
pathway have been exploited, thus requiring novel approach to further increase titers. 
 
1.3 ADAPTIVE LABORATORY EVOLUTION 
Natural evolution over long time scales resulted in all of the diversity on the 
planet. Researchers can harness the power of evolution in a “directed” manner to improve 
strains and pathways of interest.  These methods, often termed "adaptive laboratory 
evolution” utilizes some form of screening and selection to isolate beneficial mutations 
[22].  Due to the global nature of these mutations and a selection scheme, this approach is 
most amenable to debottlenecking pathways when the targets are unexplored or 
unknown.  This technique has been used to facilitate improved growth rates in diverse 
organisms and for many industrially relevant conditions such as the utilization of 
alternative carbon substrates and growth in the presence of toxic products and at low pH 
[35-41]. Selection of S. cerevisiae in the presence of inhibitory phenolic compounds 
found in lignocellulosic hydrolsate resulted in growth rate improvements of 12-57% in 
the presence of the inhibitors [35], while in E. coli, selection for growth on glycerol was 
able to increase conversion from glycerol to hydrogen by 20-fold [42]. However, one of 
the limitations associated with adaptive laboratory evolution is the ability to select for a 
phenotype of interest. Many desirable phenotypes, such as improvements in carbon flux 
 5 
through specific metabolic paths, are actually detrimental to growth.  Thus, growth 
selection will not work in these instances.   
In situations where simple growth based selection is insufficient, researchers have 
turned to implementing selection strategies tailored to a chemical feature of the desired 
product. Examples of this are the selection of floating Yarrowia lipolytica cells for high 
lipid production [12] and resistance to hydrogen peroxide resulting in a 3-fold increase in 
carotenoid production in S. cerevisiae. The integration of complex genetic circuits which 
utilize riboswitches [43] or transcription factor based biosensors [21, 44] has functioned 
to expand the range of selectable phenotypes accessible to adaptive laboratory evolution. 
Through artificial selection using fluorescence activated cell sorting (FACS) in 
Corynebacterium glutamicum, Mahr and coworkers used a transcription factor based 
biosensor to select for a 25% improvement in L-valine titers while reducing by-product 
formation by 3-4 fold [44]. The ability to select for a phenotype closely related to product 
formation demonstrates the utility of integrating biosensors into ALE strategies.  
 
1.4 WHOLE CELL BIOSENSORS 
Whole cell biosensors provide a genetically encoded method of connecting a cell 
state or metabolite level to a detectable output via transcription. These can include 
switches utilizing Förster resonance energy transfer (FRET), RNA switches which use 
analyte binding to an aptamer to activate a reporter, or inducible transcription factors that 
change expression upon analyte concentration [45]. Collectively, biosensors offer a high 
throughput mechanism to screen or select for improvements in production of their 
respective analyte, both at the enzyme [46] and genome level [44].  
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As is often the case, endogenous biosensors exist based on a cellular need to 
regulate a given pathway. One example in S. cerevisiae is the gene ARO9, which codes 
for the aromatic amino acid transferase II protein [47]. This protein is the first committed 
step in aromatic amino acid catabolism and its expression is tightly regulated [48]. 
Another source of inducibility stems from the need to modulate genes expression for 
pathways associated with carbon consumption. Examples of catabolite-inducible gene 
expression include lactose [49], galactose [50] and aromatic compounds [51] . Exploring 
these native genetic circuits has resulted in a wide variety of tools, such as strong 
inducible promoters, and diverse classes of biosensors. Biosensors are not limited to their 
native hosts, they have been recently demonstrated that they can be developed from 
heterologous parts [52] as well as imported from other host systems [43]. The rapidly 
expanding number of biosensors represents new tools to engineer proteins, evolve strains, 
and build complex genetic circuits.   
 
1.5 CONTROL OF EUKARYOTIC GENE EXPRESSION  
1.5.1 “Parts on a Shelf” for Gene Expression 
 
 Controlling gene expression is a paramount, and often foremost, goal of most 
biological endeavors—from  therapeutic antibody production [53] to the production of 
industrial enzymes [54]  to the expression of heterologous metabolic pathways [4, 55].  
While most of these efforts initially focus on the need for high expression, further work 
(especially in optimizing these processes) requires a more sophisticated, tighter control of 
gene expression.  The need for control at many levels obviates the necessity of libraries 
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of synthetic parts capable of controlling transcript levels.  However, not all parts are 
created equal and not all have been tested adequately enough to ensure function in a new 
system.  Specifically, the current synthetic biology “parts on a shelf” model seemingly 
necessitates interoperability and robustness of parts, yet relies on community sourced 
databases to assemble experimental tools [56, 57].  This reality provides both 
opportunities for rapid advancement as well as a limitation in the field.  These concepts 
are importing throughout strain engineering and biosensor development.   
1.5.2 Protein Expression Control through Transcription and Translational Rates  
 
 Two major processes contribute to protein expression level: transcriptional rates 
and translational rates.  Translation-level control (especially through tools such as 
ribosomal binding site calculators [58-60] and codon optimization) allow users to 
forward engineer the ribosomal efficiency for their gene of interest.  This approach has 
been successfully demonstrated in prokaryotic systems where strong, orthogonal viral 
promoters and simpler translational mechanisms exist.  In this context, translation-level 
control can span a 105 fold range [58] by editing a relatively small sequence space (such 
as the 5’UTR containing an RBS).  Recent work on translational control in eukaryotes 
has focused on codon optimization to allow for improved protein expression, but the level 
of control of translation is not nearly as high as in prokaryotic counterparts.  As an 
example, codon optimization of the heterologous catechol 1,2-dioxygenase gene for 
expression in S. cerevisiae resulted in a 2.9 fold increase in titer [61]. Although codon 
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optimization is a useful tool for yeast and higher eukaryotes, tuning transcription rates 
through promoters imparts a higher level of control and can achieve between a 102 fold 
dynamic range [62] and 104 range for orthogonal transcription factors [63].  Given the 
success of transcription-level control in yeast, it is important to consider both the 
synthetic parts that lead to control and the issue of robustness.   
1.5.3 Promoters 
 Promoters have one of the largest impacts on gene expression and were among 
the first parts to be studied and diversified via random mutagenesis [64].  These initial 
efforts were marked by a robust definition of promoter strength taking into account 
dilutions by growth, the promoter’s ability to impact multiple proteins, measurement of 
mRNA levels, and utility in heterologous pathway expression.  More recent efforts aim at 
creating novel promoters (independent of a native scaffold) to increase the range of 
transcriptional capacity.   
 The galactose inducible promoter (GAL) is the strongest yeast inducible 
promoter; however it suffers from complete repression by glucose.  Liang and coworkers 
developed a novel gene switch that coupled the inductive strength of the GAL promoter 
with the tight binding affinity of estradiol for the estrogen receptor protein.  This 
ultimately led to a series of parts capable of inducing a multistep pathway using 10nM 
estradiol in the presence of glucose and resulting in a 50 fold improvement in zeaxanthin 
production over previous efforts using constitutive promoters [65].  
 9 
 Some of the strongest yeast promoters have been constructed through a hybrid 
approach by coupling upstream activating sequences (UAS) with a core promoter.  
Adjusting the composition of the UAS elements enables upwards of 50 to 300 fold 
dynamic range in expression strength, reaching some of the highest reported strength of a 
promoter in S. cerevisiae [62, 66].  Improved core promoters could lead to even greater 
transcriptional control in these systems. Core promoters were investigated in the yeast 
Pichia pastoris and synthetic core promoters were designed using common sequence 
motifs and transcription factor binding sites. These synthetic core promoters were 
combined with the methanol inducible promoter pAOX1 to generate diverse activity 
between 10% to 117% of the wild-type promoter, however only fluorescent protein 
expression was reported [67].  These hybrid promoter approaches represent an 
opportunity to “dial-in” a specific quantity of an activating sequence, producing 
promoters with a specific strength. 
  
1.5.4 Trans-Acting Factors  
 
 Each of the DNA constructs described above were characterized independent of 
trans-acting factors that may be used to further augment transcription control.  Moreover, 
trans-factors can be engineered to be orthogonal to the native transcriptional machinery 
allowing for a synthetic separation of pathways and regulation.  As examples, T7 RNA 
polymerase variants were generated for E. coli that recognize unique promoter sequence 
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8 to 75 fold more than off target promoters leading to the ability to control multiple 
pathways [68].  CrisprTF’s developed by Farzadhad and co-workers based on the 
CRISPR/Cas system from Streptococcus pyogenes use an endonuclease deficient Cas9 
combined with an activation domain to enable up to 70-fold activation of desired 
promoters in HEK293T cells and S. cerevisiae [69, 70]. Trans-acting factors play a major 
part in facilitating gene expression and their engineering represents a powerful tool for 
creating high strength genetic circuits.  
1.6 SUMMARY 
 
 Metabolic engineering and synthetic biology tools have the ability to redesign 
microbial genomes to establish new organisms capable of producing a diverse array of 
chemicals of interest.  In parallel to this, adaptive laboratory evolution provides a 
mechanism to augment the production of these chemicals from laboratory scale to 
industrially relevant titers. Industrial production can be further improved by engineering 
strains to utilize inexpensive carbon sources.  Across these efforts, biosensors can 
facilitate the direct measurement of metabolites of interest and represent a potential to 
direct adaptive laboratory evolution schemes to select for phenotypes regardless of 
growth rate and overall fitness of the strain. Finally, the development of tools to control 
eukaryotic gene expression represents an important area of research which will benefit 
the fields of metabolic engineering and bioproduction.   Moreover, this control is required 
to enable both strain engineering and synthetic biology.   
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 This dissertation uniquely couples the methodologies of rational and adaptive 
strain engineering for the production of muconic acid in yeast.  The following chapters 
describe a complete story of rational engineering of a microorganism for production of 
chemical product, tool development, and the utilization of that tool to improve gene 
expression and direct the evolution of a strain capable of producing industrially relevant 
titers of our muconic acid.  Specifically, Chapter 2 describes the first heterologous 
production of muconic acid in yeast utilizing a three-step composite pathway. We then 
demonstrate further genetic modifications using metabolic modeling and feedback 
inhibition mitigation to improve titers 24-fold. Chapter 3 describes the coordinated 
engineering of cis-acting elements in concert with a mutant trans-acting factor to develop 
a strong and modular expression system. This results in an expression system capable of 
transcriptional output two-fold higher than TDH3 (GPD), one of the strongest promoters 
to-date. Finally, Chapter 5 describes the utilization of the AAA inducible promoter from 
Chapter 4 as a biosensor in an ALE selection scheme to evolve strains of yeast capable of 
increased AAA production. We then re-route flux into the composite pathway and 
produce the four-fold higher than the previous highest titer of muconic acid production. 
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Chapter 2:  Metabolic Engineering of Muconic Acid Production in 
Saccharomyces cerevisiae2 
2.1 CHAPTER SUMMARY  
 
The dicarboxylic acid muconic acid has garnered significant interest due to its 
potential use as a platform chemical for the production of several valuable consumer bio-
plastics including nylon-6,6 and polyurethane (via an adipic acid intermediate) and 
polyethylene terephthalate (PET) (via a terephthalic acid intermediate).  Many process 
advantages (including lower pH levels) support the production of this molecule in yeast.  
In this chapter, we present the first heterologous production of muconic acid in the yeast 
Saccharomyces cerevisiae.  A three-step synthetic, composite pathway comprised of the 
enzymes dehydroshikimate dehydratase from Podospora anserina, protocatechuic acid 
decarboxylase from Enterobacter cloacae, and catechol 1,2-dioxygenase from Candida 
albicans was imported into yeast.  Further genetic modifications guided by metabolic 
modeling and feedback inhibition mitigation were introduced to increase precursor 
availability.  Specifically, the knockout of ARO3 and overexpression of a feedback-
resistant mutant of aro4 reduced feedback inhibition in the shikimate pathway, and the 
zwf1 deletion and over-expression of TKL1 increased flux of necessary precursors into 
the pathway.  Further balancing of the heterologous enzyme levels led to a final titer of 
nearly 141 mg/L muconic acid in a shake-flask culture, a value nearly 24 fold higher than 
                                                 
2 Curran, K. A., Leavitt, J. M., Karim, A. S., Alper, H. S., Metabolic engineering of muconic acid 
production in Saccharomyces cerevisiae. Metabolic engineering 2013, 15, 55-66. The author made 
significant contributions to designing, conducting and analyzing the experiments as well as preparing and 
editing the manuscript.  
 13 
the initial strain.  Moreover, this strain has the highest titer and second highest yield of 
any reported shikimate and aromatic amino acid-based molecule in yeast in a simple 
batch condition.  This chapter collectively demonstrates that yeast has the potential to be 
a platform for the bioproduction of muconic acid and suggests an area that is ripe for 
future metabolic engineering efforts. 
2.2 INTRODUCTION 
Worldwide pressures to reduce petroleum footprints have increased interest in 
alternative, renewable methods to produce nearly all commodity and specialty chemicals.  
To this end, the field of metabolic engineering has begun to answer this demand through 
the development of organisms that can produce an increasingly diverse array of 
chemicals [4, 71-74].  In particular, bio-plastics have become an especially potent area as 
demonstrated by the metabolic engineering of strains for production of precursors such as 
succinic acid, ethylene glycol (from bio-ethanol), 1,3-propanediol, 1,4-butanediol, ρ-
hydroxystyrene, styrene, as well as the development of novel bio-plastics such as 
polylactides and polyhydroxyalkanoates [75-83].  Beyond this list, muconic acid serves 
as another interesting precursor and platform chemical for producing several bio-plastics.  
Muconic acid is easily converted via hydrogenation into adipic acid, a chemical used to 
produce nylon-6,6 and polyurethanes.  Additionally, muconic acid can be converted via 
the Diels-Alder reaction with acetylene and subsequent oxidation into terephthalic acid, 
one of two primary constituents in the plastic polyethylene terephthalate (PET).  
Terephthalic acid is also used in the production of polyester.  World production of adipic 
acid and terephthalic acid is over 2.8 and 71 million tonnes, respectively [84, 85].  At 
present, both of these chemicals are primarily produced from non-renewable petroleum 
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feedstock and toxic intermediates, thus warranting a sustainable, biosynthetic production 
platform. 
 Muconic acid is not endogenously produced from carbohydrates by any known 
organism.  However, muconic acid can be found during the catabolism and detoxification 
of aromatic compounds by some organisms, including yeast such as Candida sp., and 
bacteria such as Acinetobacter sp., Rhodococcus sp., and Sphingobacterium sp., among 
others [86-89]. Previously, Draths and Frost engineered a recombinant Escherichia coli 
to produce muconic acid from glucose via a heterologous synthetic pathway drawing 
from a naturally occurring intermediate in the shikimate pathway, 3-dehydroshikimate 
(DHS) [26, 90].  In this synthetic, composite pathway, DHS is converted to 
protocatechuic acid (PCA) via a DHS dehydratase cloned from Klebsiella pnemoniae, 
PCA is then converted to catechol via a PCA decarboxylase from K. pnemoniae, and 
finally catechol is converted to cis,cis-muconic acid via a catechol 1,2-dioxygenase from 
Acinetobacter baylyi (Figure 2.1).  This pathway along with some minor modifications 
of metabolism enabled the production of muconic acid in E. coli.   
 Many industrial biotechnological processes are moving toward using yeasts as 
platform organisms due to their many advantages.  The yeast Saccharomyces cerevisiae 
is an ideal host organism for industrial chemical production because it offers advantages 
including withstanding lower temperatures, easier separations, no phage contaminations, 
suitability in large-scale fermentation, lower pH fermentations, and generally higher 
tolerances.  S. cerevisiae has been explored as a host for producing heterologous models 
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that utilize precursors in the shikimate and aromatic amino acid pathways such as 
vanillin, ρ-hydroxybenzonic acid, ρ-amino benzoic acid, ρ-hydroxycinnamic acid, 
resveratrol and naringenin [29, 30, 32, 33, 91-93].  These examples and advantages raise 
the possibility of using yeast as a platform for the production of muconic acid.  
Additionally, S. cerevisiae naturally prefers a lower pH environment than E. coli, a 
condition better suited for producing a di-acid.  Here, we present the first reported 
production of muconic acid in the yeast S. cerevisiae.  Through a series of strain 
modifications, yields were increased more than 20-fold from the initial parental strain and 
resulted in the highest titer of an aromatic-based molecule in a yeast shake-flask (over 
140 mg/L) and among the highest yields.   
  
2.3 RESULTS 
2.3.1 Enzyme characterization and pathway assembly 
Since muconic acid is not an endogenous metabolite, it is necessary to recreate a 
synthetic production pathway in yeast.  To create the initial pathway, we sought to utilize 
the same three enzymes classes employed to produce muconic acid in E. coli [26].  This 
pathway converts DHS, an intermediate in the shikimate pathway (and ultimately the 
aromatic amino acid biosynthesis pathways) into muconic acid in three steps (Figure 
2.1).  These three steps are carried out by a DHS dehydratase, a PCA decarboxylase, and 
a 1,2-catechol dioxygenase.   
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Figure 2.1 Composite heterologous pathway for muconic acid production.   
 
The synthetic pathway for muconic acid is depicted in the context of the shikimate 
pathway in yeast.  The following metabolite abbreviations are used: PEP is 
phosphoenolpyruvate, E4P is erythrose-4-phosphate, DAHP is 3-deoxy-D-
arabinoheptulosonate-7-phosphate, DHQ is dehydroquinate, DHS is dehydroshikimate, 
and PCA is protocatechuic acid. 
 
   A two-step approach was employed to identify heterologous enzymes for this 
synthetic pathway.  First, candidate DHS dehydratase and catechol 1,2-dioxygenase 
enzymes were individually expressed in S. cerevisiae and tested for activity using an in 
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vitro enzyme assay.  These tests were straight-forward due to the availability of a 
spectrophotometric enzyme assay.  Second, the best performing DHS dehydratase and 
catechol 1,2-dioxygenase were co-expressed along with each candidate PCA 
decarboxylase enzyme and tested for the ability to complete the pathway and produce 
muconic acid.  This complementation type assay was conducted due to the lack of a 
suitable in vitro PCA decarboxylase enzyme activity assay.  
Several DHS dehydratase enzymes have been previously characterized and 
studied in literature.  The AroZ gene from K. pneumoniae encodes a DHS dehydratase 
that has previously been heterologously expressed in E. coli [26, 90].  However, this gene 
has never been expressed in S. cerevisiae and its function was uncertain given its 
bacterial origin.  As a result, this gene was codon- and expression-optimized for S. 
cerevisiae and synthesized by Blue Heron Biotech to create the plasmid p413-TEF-
kpAroZopt.  The non-optimized version of the gene was also cloned and tested in this 
chapter (the resulting plasmid was named p413-TEF-kpAroZ).  Additional AroZ 
homologues have either been identified in literature or could be selected on the basis of 
sequence homology.  The gene Pa_5_5120 from P. anserina (also known as P. pauciseta) 
is a DHS dehydratase that has been successfully expressed in S. cerevisiae as a first step 
in the pathway to produce vanillin [29].  As a result, we also codon- and expression-
optimized this gene and produced the plasmid p413-TEF-pa5_5120opt.  Another well-
studied DHS dehydratase gene is the QutC gene from Aspergillus sp. [94].  This gene 
from A. niger was likewise codon- and expression-optimized and included in this chapter 
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as plasmid p413-TEF-anQutCopt.  Finally, a potential homologue from D. hansenii was 
identified via a BLAST search of the fungi kingdom using the K. pneumoniae AroZ gene 
as a search query.  This gene was cloned directly from D. hansenii gDNA and included in 
this chapter as plasmid p413-TEF-dhDEHA2F15906g.  These four genes (five 
combinations as K. pneumoniae AroZ was included in both codon optimized and non-
optimized form) were each individually expressed in S. cerevisiae on a low copy plasmid 
using a strong TEF promoter and assayed for activity.   
Transformed cells were grown and cell extracts were harvested and tested for in 
vitro DHS dehydratase activity via a spectrophotometric assay.  Only two of the five 
DHS dehydratase constructs yielded active enzymes with detectible in vitro kinetic 
activity; the codon-optimized forms from K. pnemoniae and from P. anserina.  
Experimentally measured kinetic constants (Km and Vmax) were nearly two-fold more 
favorable for the P. anserina DHS dehydratase over the K. pneumonia AroZ (Table 2.4, 
at the end of the chapter).  These results demonstrated the superiority of the fungal source 
for expression in yeast of this particular enzyme.   
 Next, we sought to identify a suitable catechol 1,2-dioxygenase for the muconic 
acid synthetic pathway.  Similarly to the DHS dehydratase genes, several genes from 
both bacterial and fungal sources were tested on the basis of in vitro activity of cell 
lysate.  First, both the wild-type and codon- and expression-optimized versions of the 
CatA gene from A. baylyi were tested (plasmids p413-TEF-abCatA and p413-TEF-
abCatAopt).  The wild-type version of this gene was previously used in E. coli for the 
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assembly of a muconic acid pathway [26, 90].  Next, the HQD2 gene from C. albicans 
[95] was codon- and expression-optimized and expressed in plasmid p413-TEF-
caHQD2opt.  Finally, a homologue to the CatA gene was found in D. hansenii using a 
BLAST search.  This gene was cloned directly from gDNA and expressed in plasmid 
p413-TEF-dhDEHA2C14806g.    
 Unlike the AroZ selection, all of the four putative catechol 1,2-dioxygenase were 
proven to be active on the basis of in vitro activity assays (Table 2.5, at the end of the 
chapter).  However, the enzyme kinetics did not immediately point toward the superiority 
of one particular CatA gene and thus an additional in vivo feeding assay was conducted.  
To do so, 1 g/L catechol was added to stationary phase cultures expressing each catechol 
1,2-dioxygenase enzyme and supernatants were assayed for muconic acid using HPLC 
after 24 hours of culture.  Using this feeding assay, the HQD2 gene from C. albicans 
produced the largest amount of muconic acid (Figure 2.2) and was selected as the 
candidate gene moving forward.   Moreover, in this assay, we were able to account for all 
1 g/L of catechol after 24 hours as either free catechol or muconic acid product, thus 





Figure 2.2 Production of muconic acid from catechol 1,2-dioxygenase-expressing strains.   
To test for in vivo function of the catechol 1,2-dioxygenases, muconic acid concentration 
in the culture supernatant was measured using HPLC 24 hours after flasks were spiked 
with 1 g/L catechol.  Standard deviation values are based on results from biological 
triplicates. 
 
Finally, once the DHS dehydratase and catechol 1,2-dioxygenase enzymes were 
chosen for the yeast synthetic muconic acid pathway, several PCA decarboxylase 
candidates were characterized.  The AroY gene from K. pneumoniae was codon- and 
expression-optimized and was expressed in plasmid p416-TEF-kpAroYopt.  The wild-type 
gene, which has previously been expressed in E. coli [26, 90], was also characterized 
using plasmid p416-TEF-kpAroY.  The gene ECL_01944 from E. cloacae was also 
codon- and expression-optimized and expressed in plasmid p416-TEF-ECL_01944opt  
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[96, 97].  Additionally, a BLAST search was used to look for possible K. pneumoniae 
AroY homologues in the fungal kingdom.  The DEHA2G00682g gene from D. hansenii 
was identified and cloned from gDNA (plasmid p416-TEF-dhDEHA2G00682g).  
Additionally, we hypothesized that the FDC1 and PAD1 genes from S. cerevisiae, which 
together are known to be phenylacrylate decarboxylases [98], may have some PCA 
decarboxylase activity.  As a result, these two genes were cloned and co-expressed on a 
single plasmid (plasmid p416-TEF-scFDC1/PAD1).  Finally, the annotated genome for 
P. anserina lists two 2,3-dihydroxybenzoic acid decarboxylases, Pa_0_880, and 
Pa_4_4540  (PCA is 3,4-dihydroxybenzoic acid).  We hypothesized that one of these 
could also have promiscuous PCA decarboxylase activity and therefore codon- and 
expression-optimized these genes and cloned them in plasmids p416-TEF-pa0_880opt and 
p416-TEF-pa4_4540opt.  These six different genes (seven total variations) were 
transformed into yeast and tested using an in vivo pathway completion assay due to the 
lack of a simple in vitro enzymatic assay for the PCA decarboxylase. 
Each of the PCA decarboxylase candidates was expressed in a strain that also 
harbored plasmids containing the DHS dehydratase gene from P. anserina and the HQD2 
gene from C. albicans (p413-TEF-pa5_5120opt and p415-GPD –caHQD2opt) and tested 
for muconic acid production using HPLC.  Strains were cultivated in shake flask 
conditions with a starting OD600 of 0.25.  Muconic acid concentration was quantified in 
the culture supernatant after 48 hours of culture.  Only the PCA decarboxylases from K. 
pnemoniae and E. cloacae were active, and the two codon-optimized enzymes had 
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similar production values (Table 2.6, at the end of the chapter).  The strain with AroY 
from K. pnemoniae was named MuA01 and was used first in this chapter.  It was 
discovered that the E. cloacae gene performed better in more optimized strains and was 
used strains developed later in this chapter.  Not only did this experiment identify active 
PCA decarboxylase enzymes, it also represented the first time that muconic acid has been 
successfully produced in S. cerevisiae.  Titers were very low (around 5 mg/L) indicating 
that more extensive strain and pathway engineering was necessary. 
 
2.3.2 Relief of Amino Acid Feedback Repression  
Aromatic amino acid biosynthesis is a tightly regulated process with the flux of 
intermediates in the shikimate and aromatic pathways subject to significant allosteric 
regulation [99].  To determine the magnitude of impact in our strain, we assayed the 
effect of exogenous repression by removing amino acid supplementation in the media.  
Culturing strain MuA01 in a synthetic minimal media (YSM) lacking the exogenous 
aromatic amino acids was shown to increase muconic acid production three-fold over a 
synthetic complete media (YSC) (Figure 2.3).  These results demonstrate that feedback 
inhibition caused by the aromatic amino acids in the media was limiting flux to the 
muconic acid pathway and also implicated that intracellular endogenous production may 




Figure 2.3 Muconic acid production across strains used in this chapter.   
Muconic acid levels are provided in the progression from first pathway assembly to the 
final, optimized strain.  These strain names are described in more detail with genotypes in 
Table 2.2.  All values were determined by HPLC after at least 48 hours of batch flask 
culture.  Strains were grown in complete synthetic media (YSC) unless marked as 
follows:  *Strains grown in minimal synthetic media (YSM), **Strains grown in 
complete synthetic media (YSC) with 40 g/L glucose.  Standard deviations are based on 
biological triplicates. 
 
We next removed known feedback inhibition through genetic modification.  Entry 
into the shikimate pathway from the pentose phosphate and glycolytic pathways is 
governed by 3-deoxy-D-arabinoheptulosonate7-phosphate (DAHP) synthase, an enzyme 
that catalyzes the condensation of phosphoenolpyruvate and erythrose-4-phosphate to 
DAHP.  Yeast has two isozymes of DAHP synthase that are regulated independently by 
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phenylalanine (ARO3) and tyrosine (ARO4) feedback inhibition.  It has been previously 
shown that knocking out both ARO3 and ARO4 and over-expressing a mutant version, 
aro4k229l, can alleviate the feedback inhibition in this step [100].  Therefore, serial gene 
deletion was performed to obtain an aro3 aro4 double knockout the BY4741 strain, 
resulting in strain MuA02.  Next, a plasmid containing the mutant aro4k229l (p416-TEF-
aro4k229l) was transformed along with the three muconic acid pathway genes (on 
plasmids p415-GPD-caHQD2opt and p413-TEF-pa5_5120opt/TEF-kpAroYopt).  For 
comparison, the wild type ARO4 gene was also over-expressed on plasmid p416-TEF-
scARO4 in the same background.  The strain with ARO4 was named MuA03 and the 
strain with aro4k229l was named MuA04.  The strain expressing aro4k229l achieved a 50% 
increase in muconic acid production over wild-type ARO4, producing 21 ± 2 mg/L and 
14 ± 2 mg/L, respectively (Figure 2.3).  Furthermore, unlike the wild-type ARO4, the 
strain expressing aro4k229l produced the same amount of muconic acid in both YSC and 
YSM, demonstrating that the feedback inhibition in the pathway had been removed.  
Subsequently, aro4k229l was integrated into the ARO4 genomic locus under control of the 
GPD promoter (strain MuA06). 
 
2.3.3 Over-expression and balancing of heterologous pathway enzymes 
Due to the fact that the muconic acid pathway is a synthetic, composite pathway 
comprised of enzymes from several different sources, the enzyme activities and 
expression levels require proper balancing.  When pathway intermediate concentrations 
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were measured in addition to muconic acid, it was immediately apparent that PCA 
decarboxylase is an important rate limiting step in the pathway.  For example, in strain 
MuA04, the PCA concentration reached more than seven times the level of muconic acid, 
to 166 ± 11 mg/L.  To address this bottleneck, the PCA decarboxylase gene was changed 
from the K. pneumoniae AroYopt to ECL_01944opt from E. cloacae, an enzyme with a 
slightly higher initial muconic acid production in enzyme evaluations described above 
(Table 2.6, at the end of the chapter).  ECL_01944opt was also cloned into a high copy 2µ 
plasmid (plasmid p425-GPD-ECL_01944opt) instead of the centromeric plasmid 
originally used (strainMuA05).  This change resulted in an increase of muconic acid 
production to 25 ± 1 mg/L (Figure 2.3).  The PCA decarboxylase gene was subsequently 
further over-expressed by integrating it into the Ty2 retrotransposon δ elements multiple 
times under the control of the GPD promoter using the pITy3 vector [101] (strain 
MuA07).  This integration did not appreciatively increase the production of muconic acid 
although it did increase the mRNA expression of the gene roughly 3-fold (Figure 2.4).  
As a result, it is likely that the problems associated with PCA decarboxylase are post-
transcriptional in nature.  In the final muconic acid producing strain, the PCA 
decarboxylase was over-expressed using both multiple genomic integrations and a high 
copy plasmid (Subchapter 2.3.5).  Finally, the other two pathway enzymes, DHS 
dehydratase and catechol 1,2-dioxygenase, were over-expressed on high-copy plasmids 
to further improve the pull of metabolites through the synthetic pathway (strain MuA08).  
Collectively, these changes increased the production of muconic acid to 30  ± 1 mg/L 





Figure 2.4  Transcript levels for PCA decarboxylase overexpression strains.   
Select strains with overexpression of the PCA decarboxylase gene ECL_01944opt either 
by multi-copy plasmid or multi-copy integration were measured by RT-PCR.  Strains are 
described in Table 2.2.  Transcript levels increased with successive genetic engineering.  
Standard deviation values are based on three technical replicates. 
 
2.3.4 Flux balance analysis allows for further improvements in precursor 
availability 
To identify additional targets for metabolic engineering of muconic acid in S. cerevisiae, 
we next utilized the framework of flux balance analysis.  A similar approach has been 
previously used to improve metabolite production for a variety of products [102-108].  
The genomic model iMM904 [109] was used as a starting point and additional reactions 
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were included to account for the heterologous muconic acid pathway (Table 2.3, at the 
end of the chapter).  In order to calculate the maximum theoretical yield, the system of 
linear equations was solved while maximizing the reaction for muconic acid production.  
This resulted in a value of 85.7% mol/mol from glucose.  It was immediately noted, 
however, that this solution required maximizing the flux of fructose-6-phosphate and 
glyceraldehyde-3-phosphate through the transketolase reaction in the pentose phosphate 
pathway to produce erythrose-4-phosphate and xylulose-5-phosphate.  This flux mode 
balances the availability of erythrose-4-phosphate and phosphoenolpyruvate and avoids 
the oxidative shunt of the pentose phosphate pathway.  However, it is unlikely that this 
flux mode occurs endogenously in vivo due to kinetic constraints [110].  It is more likely 
that flux enters into the pentose phosphate pathway through the glucose-6-phosphate 
dehydrogenase reaction and that the transketolase reaction utilizes erythrose-4-phosphate 
and xylulose-5-phosphate to produce fructose-6-phosphate and glyceraldehydes-3-
phosphate (the reverse of what is desired).  When we forced flux to go toward this route 
in the in silico model, the maximum theoretical yield was decreased to 60.9% mol/mol 
glucose.  These results suggest the need for a genetic modification to rewire the pentose 
phosphate pathway flux. 
In order to implement this desired flux network in vivo, two genetic steps were 
taken.  First, the transketolase gene, TKL1, was over-expressed on p413-TEF-scTKL1 
(strain MuA09) to help favor the kinetically hindered pathway.  Second, the glucose-6-
phosphate dehydrogenase gene, ZWF1, was knocked out (strain MuA10) to force entry 
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into the pentose phosphate pathway to occur via transketolase.  When these modifications 
were combined in the same strain (strain MuA11), the muconic acid titer increased two-
fold over the previous best strain, to a value of 62 ± 4 mg/L (Figure 2.3).   
 
2.3.5 Final muconic acid-producing strain characterization  
To further increase the muconic acid production in the strain developed above, the 
PCA decarboxylase gene was over-expressed on a high copy plasmid (p426-GPD-
ECL_01944opt) in addition to being integrated multiple times onto the chromosome 
(strain MuA12).  This increased the PCA decarboxylase gene RNA expression by 64% 
over the previous strain (Figure 2.4), and increased the muconic acid production to 77 ± 
1 mg/L (Figure 2.3) with a yield of 3.9 mg/g glucose.  Finally, we modified the glucose 
content of the medium by growing MuA12 in YSC media with 40 g/L glucose 
supplementation for an extended period of 108 hr (Figure 2.5) after initial seeding at an 
OD600 of 0.25.  The final muconic acid titer in this strain was 141 ± 1 mg/L.  This strain 
produced the highest amount of muconic acid in this chapter (nearly 24 times the value 
produced by the initial strain) and represents the highest titer of an aromatic-based 
molecule produced in yeast in a simple shake-flask condition to date (Table 2.7, at the 






Figure 2.5 Fermentation profile of final muconic acid strain MuA12.   
The concentration of muconic acid, PCA, catechol, and glucose in the culture supernatant 
was measured over time from a shake-flask experiment.  Muconic acid levels reached the 
highest titer reported for an aromatic based molecule of nearly 141 mg/L.  Glucose 
concentrations were measured using the YSI bioanalyzer, all others were measured using 
HPLC.  Glucose values are plotted on the left axis while remaining metabolites are 




This chapter reports the first successful heterologous production of muconic acid 
in the yeast Saccharomyces cerevisiae.  To accomplish this production, we assembled a 
synthetic, composite pathway comprised of three distinct enzymes.  The DHS 
dehydratase gene from P. anserina was easily identified as the best among the candidate 
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enzymes tested.  This finding is corroborated with a previous report demonstrating 
successful use of this enzyme in S. cerevisiae for the production of vanillin [29].  In 
contrast, none of the catechol 1, 2-dioxygenase candidates demonstrated a difference in 
catalytic activity in the first in vitro assay.  However, it became clear after an in vivo 
feeding assay that the gene from C. albicans had a higher capacity.  It is also interesting 
to note that for the K. pnuemoniae CatA gene, the un-optimized form showed better 
activity than the codon-optimized form of the gene.  This finding is an interesting result 
that challenges the need to always codon-optimize heterologous genes.  Finally, the 
second step of the pathway, the PCA decarboxylase, proved the most difficult to identify 
and still remains the bottleneck of the pathway (as evinced by the high PCA 
concentration in Figure 2.5).  Very few PCA decarboxylase genes have been studied in 
detail and only the AroY from Klebsiella species and ECL_01944 from Enterobacter 
cloace have even been sequenced [97, 111].  Furthermore, to our knowledge, no PCA 
decarboxylase has been identified in eukaryotes.  In this chapter, we tested several 
potential eukaryotic enzymes, but unfortunately none possessed the desired activity.  
Consequently, it was not surprising to discover that PCA decarboxylase remains as a rate 
limiting step in this pathway.  High over-expression of the PCA decarboxylase gene 
ECL_01944opt partially relieved the pathway bottleneck, but future efforts to engineer 
this enzyme for better activity in S. cerevisiae would be beneficial.   
Despite challenges in selecting high flux-supporting enzymes for this synthetic, 
composite pathway, we achieved the highest titer of an aromatic-based or shikimate 
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based molecule in yeast in a simple, batch shake-flask condition.  Moreover, the 
maximum yield we achieved of 3.86 mg/g glucose was the second highest among all 
published reports (Table 2.7, at the end of the chapter).  Any success in surpassing these 
values has been achieved by significant optimization of culturing conditions in a bio-
reactor, such as for the production of vanillin [102], or in the conditioning and optimizing 
of an industrial strain, such as in the production of resveratrol [112].  These results 
highlight a remaining, significant challenge for yeast metabolic engineering.  Indeed the 
greatest gains in titer achieved in this chapter were due to genetic alterations in the 
upstream pathway.  Specifically, over-expression of the feedback resistant aro4k229l 
(strain MuA3) increased production more than three-fold over the initial strain, MuA01.  
Furthermore, rewiring of the pentose phosphate pathway to avoid the oxidative shunt 
(strain MuA11) increased production two-fold (over MuA08).  Yet, total net flux through 
the shikimate pathway in yeast is limited.  There are additional potential targets for 
improving this heterologous pathway.  Additional gene knockout targets have been 
suggested by flux balance analysis, including some (such as ∆pdc1) that have 
successfully increased the production of vanillin in S. cerevisiae [102].  Beyond gene 
deletions, it is possible to also augment the shikimate pathway to divert more DHS into 
the synthetic muconic acid pathway.  Specifically, the ARO1 gene, a penta-functional 
enzyme that catalyzes the majority of the steps in the shikimate pathway [113, 114], may 
be altered to help reduce the flux of dehydroshikimate into shikimate, thereby shifting the 
balance of production from the aromatic amino acids to muconic acid.  It is interesting to 
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note that this penta-functional enzyme is unique to yeast as compared to E. coli in which 
each of these enzymatic functions is encoded by a separate gene.  As such, knockout of 
the aroE gene in E. coli proved to be simple method to improve muconic acid production 
[90]. 
Despite the potential targets described above, it is clear that aromatic amino acid 
based production in yeast is an outstanding metabolic engineering challenge.  In contrast, 
straight-forward genetic modifications such as alleviating feedback inhibition in E. coli 
can result in high gram per liter levels of aromatic amino acids and their related products 
[115-117].  Indeed, muconic acid can be produced at such levels in E. coli as well [26, 
90].  The inability to achieve higher production values from rational metabolic 
engineering techniques in yeast suggests that flux in the shikimate and aromatic amino 
acid pathways is highly regulated, likely through both global and local transcription 
machinery.  A comprehensive ‘omics analysis of amino acid production in yeast [118] 
demonstrates significant allosteric and transcriptional regulation throughout the various 
amino acid pathways, partially controlled by factors such as Gcn4p.  Further analysis of 
the improved strains here can identify similar regulatory proteins that are responsible for 
controlling overall flux through the shikimate pathway.  Once these targets are identified, 
techniques such as global Transcription Machinery Engineering [119, 120] can be used to 
further increase the yield and titer in S. cerevisiae.  A recent report has demonstrated that 
the application of gTME using global regulatory factors can improve L-tyrosine 
production in E. coli [121].Similar improvements would ultimately aid in making yeast a 
 33 
suitable platform for shikimate-based molecules especially when coupled with the 
process advantages and lower pH tolerance that yeast possesses over E. coli.   
2.4 CONCLUSION 
In summary, this chapter provides the first demonstration that muconic acid can 
be produced in S. cerevisiae and that metabolic engineering can be used to increase 
production titers by nearly 24 fold over the initial strain.  This chapter presents a strain 
with the highest titer and second highest yield of any shikimate and aromatic amino acid-
based molecule in yeast in a simple batch condition.  Beyond this proof-of-concept, the 
genetic alterations utilized here create an excellent starting point from which additional 
metabolic engineering, strain development, and global regulatory engineering can be 
performed in order to further increase titer and yield.  These results demonstrate an 
unanswered challenge of metabolic engineering in yeast.  Nevertheless, these results 
demonstrate that yeast can serve as a host organism for the production of sustainable bio-
plastics and polymer precursors. To facilitate the selection of further improvements in 
muconic acid production, our next step is to engineer a biosensor which can detect the 
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p416-TEF-scaro4k229l Mutated aro4 gene 
from S. cerevisiae 







P416-GPD- scaro4k229l Mutated aro4 gene 










from E. cloacae 













from E. cloacae 









Table 2.1: continued next page. 
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from P. anserina 
and PCA 
decarboxylase from 

























































P413-TEF-scTKL1 TKL1 gene from S. 
cerevisiae 













gene from E. 
cloacae expressed 







Table 2.1: continued next page. 
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Plasmid Name Characteristics Primers 
pUG6 Plasmid containing 
KanMX gene with 
loxP sites 










































Table 2.1: continued next page. 
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Plasmid Name Characteristics Primers 
pSH47 Plasmid containing 
Cre recombinase 
under control of 
GAL1 promoter for 




Table 2.1  Plasmids used in this chapter.   
All plasmids were made from plasmids described in [122] with the exception of pITy-
GPD- ECL_01944opt from the pITy3 vector [101]and pUG6 and pSH47 [123].  Primers 





Strain Genotype Plasmids Parent 
Strain 
Reference 
BY4741 Mat a; his Δ1; leu2Δ0; 
met15Δ0; ura3Δ0 
none   Euroscarf 
Y00000  
MuA01 Mat a; his Δ1; leu2Δ0; 
met15Δ0; ura3Δ0 






MuA02 Mat a; his Δ1; leu2Δ0; 





MuA03 Mat a; his Δ1; leu2Δ0; 










MuA04 Mat a; his Δ1; leu2Δ0; 










MuA05 Mat a; his Δ1; leu2Δ0; 










MuA06 Mat a; his Δ1; leu2Δ0; 





MuA07 Mat a; his Δ1; leu2Δ0; 






MuA08 Mat a; his Δ1; leu2Δ0; 










MuA09 Mat a; his Δ1; leu2Δ0; 










Table 2.2: continued next page. 
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Strain Genotype Plasmids Parent 
Strain 
Reference 
MuA10 Mat a; his Δ1; leu2Δ0; 







MuA11 Mat a; his Δ1; leu2Δ0; 












MuA12 Mat a; his Δ1; leu2Δ0; 












Table 2.2  Yeast strains used in this chapter.   
A table of yeast strains generated in this chapter and the corresponding genotype. 
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Reaction Name Reaction Formula 
‘AROZ’ 3dhsk[c]  -> h2o[c] + pca[c] 
‘AROY’ pca[c] -> co2[c] + cat[c] 
‘CATA’ o2[c] + cat[c] -> mua[c] 
‘MUAe’ mua[c] <=> mua[e] 
‘EX_MUA’ mua[e] <=>   
 
Table 2.3  Reactions added to iMM904 model to account for the heterologous muconic 
acid pathway.   
The heterologous pathway for muconic acid was added to the standard genome scale 
model.  The following abbreviations are used: 3dhsk is 3-dehydroshikimate, h2o is water, 
pca is protocatechuic acid, co2 is carbon dioxide, cat is catechol, o2 is oxygen, and mua 
















AroZ Codon-optimized 0.65 ± 0.09 (1.0 ± 
0.16)x10-4 
Aspergillus niger QutC Codon-optimized n.d. n.d. 
Podospora 
anserina  




DEHA2F15906g Not optimized 
 
n.d. n.d. 
Table 2.4  In vitro assay of DHS dehydratase genes.   
A spectrophotometric assay using cell lysates was conducted to compare catalytic 
constants for candidate DHS dehydratase genes.  Km and Vmax standard deviation values 




Species  Gene  Optimization Km (mM)  Vmax (mM/min/µg 
protein extract)  
Acinetobacter baylyi  CatA Not optimized 0.16 ± 0.05  (4.1 ± 0.7)x10-4   




0.23 ± 0.04  (1.2 ± 0.3)x10-4   
Debaryomyces hansenii  DEHA2C14806g Not optimized 
 
0.23 ± 0.06 (2.2 ± 0.4)x10-4  
 





0.17 ± 0.03 (2.8 ± 0.2)x10-4  
 
Table 2.5  In vitro assay of catechol 1,2-dioxygenase genes 
A spectrophotometric assay using cell lysates was conducted to compare catalytic 
constants for candidate catechol 1,2-dioxygenase genes.  Km and Vmax standard 
deviation values are based on results from biological triplicates.   
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Species  Gene  Optimization Muconic acid 
production (mg/L) 
Klebsiella pneumoniae AroY Not optimized 3.9 ± 0.1 
Klebsiella pneumoniae AroY Codon-optimized 4.4 ± 0.8 
Debaryomyces hansenii DEHA2G00682g Not optimized n.d. 
Podospora anserina  Pa_0_880 Codon-optimized n.d. 
Podospora anserina  Pa_4_4540 Codon-optimized n.d. 
Saccharomyces cerevisiae FDC1 and PAD1 Not optimized n.d. 
Enterobacter cloacae ECL_01944 Codon-optimized 5.3 ± 0.3 
 
Table 2.6  In vivo assay of PCA decarboxylase genes co-expressed with Pa_5_5120 from 
P. anserina and HQD2 from C. albicans.   
Candidate PCA decarboxylase enzymes were assayed through an in vivo pathway 
complementation assay.  Muconic acid production standard deviation values are based on 








Maximum Yield  Reference 
Muconic acid Dehydroshikimate 141±8 3.9±0.2 mg/gGlucose This chapter 
Vanillin Dehydroshikimate 45 2.3 mg/gGlucose [29] 
p-hydroxybenzoic 
acid 
Tyrosine 89.8 6.0 mg/gGlucose [30] 
p-amino benzoic 
acid 
Chorismate 34.3 2.3 mg/gGlucose [30] 
p-hydroxycinnamic 
acid 
Phenylalanine 33.3 1.7 mg/ gRaffinose [31] 
Resveratrol Phenylalanine 14.4 0.22 mg/gCoumaric acid [32] 
Naringenin Tyrosine 7 0.35 mg/gGalactose [33] 




Table 2.7  Compilation of shikimate or aromatic amino acid-based metabolite production 
in yeast for simple shake-flask conditions.  
Metabolite titers and yields are compared for similar molecules produced in 
metabolically engineering S. cerevisiae.  The strain described in this chapter has the 
highest titer and the second highest yield to date for this class of molecules. 
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Chapter 3:  Coordinated Transcription Factor and Promoter 
Engineering to Establish Strong Expression Elements in Saccharomyces 
cerevisiae3 
3.1 CHAPTER SUMMARY 
In pursuit of a biosensor which can facilitate further improvements in muconic 
acid production, we identified a transcription factor and promoter sensitive to the 
downstream products of the shikimate pathway and used them to develop tools for gene 
expression. In this chapter, we present a coordinated approach that combines cis-acting 
element engineering with mutant trans-acting factors to engineer yeast promoters.  
Specifically, we first construct a hybrid promoter based on the ARO9 upstream region 
that exhibits high constitutive and inducible expression with respect to exogenous 
tryptophan.  Next, we perform protein engineering to identify a mutant Aro80p that 
affords both high constitutive expression while retaining inducible traits.  We then use 
this mutant trans-acting factor to drive expression and generate ultra-strong promoters 
with transcriptional output roughly 2 fold higher than TDH3 (GPD), one of the strongest 
promoters to-date.  Finally, we used this element to construct a modular expression 
system capable of staged outputs resulting in a system with nearly 6-fold, 12-fold and 15-
fold expression relative to the off-state. This chapter further highlights the potential of 
using endogenous transcription factors (including mutant factors) along with hybrid 
promoters to expand the yeast synthetic biology toolbox.  
 
                                                 
3 Leavitt, J. M., Tong, A., Tong, J., Pattie, J., Alper, H. S., Coordinated transcription factor and promoter 
engineering to establish strong expression elements in Saccharomyces cerevisiae. Biotechnology 
journal 2016. The author made significant contributions to designing, conducting and analyzing 
the experiments as well as preparing and editing the manuscript.  
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3.2 INTRODUCTION 
Precise control of gene expression is essential for many applications including 
protein production, metabolic engineering, and synthetic biology [124].  This control is 
the result of both cis-acting elements and trans-acting factors that interact to determine 
transcriptional capacity.  In recent years, our capacity to influence these elements and 
factors has increased, thus yielding an increase in the number of distinct promoter 
modalities available for many model host organisms.  However, the common eukaryotic 
model yeast Saccharomyces cerevisiae is still transcriptionally limited compared with the 
tools available in common bacterial hosts such as Escherichia coli [58, 125-129].  
Nevertheless, the attractiveness of yeast as a platform organism (especially for metabolic 
engineering applications) [4, 5, 7] warrant continued efforts to expand the set of tools 
available.  Most synthetic biology efforts in S. cerevisiae have focused primarily focused 
on cis-elements as a means of influencing transcriptional output via modifications to the 
promoter sequence and control of RNA half-life through terminator sequence [62, 130, 
131].  In this vein, significant efforts have been made in cataloging the binding sites for 
various transcription factors within promoter sequences as well as characterizing their 
relative importance [132, 133].  While these efforts have been effective at modulating 
(and sometimes, increasing) promoter activity, there are still only a limited number of 
orthogonal systems in yeast as well as a limited set of inducible promoters.   
The engineering of trans-acting factors enables an additional level of expression 
control that is compatible with generating more inducible promoters and further complex 
genetic circuits.  Indeed, previous efforts for trans-acting factor engineering in yeast has 
focused on importing orthogonal trans-elements from other systems such as TALE’s, 
dCas9, bacterial response elements [134], and Estrogen Receptors [70, 135, 136].  When 
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coupled with the proper cis-factor architecture, these systems have provided additional 
levels of inducible control and have facilitated multi-gene activation.  However, with few 
exceptions, these systems have not provided tools which facilitate novel, strong 
transcriptional activation above currently existing systems.   
Despite promise of orthogonal trans-factors for expanding the range of inducible 
systems in yeast, the set of inducible promoters for S. cerevisiae remains limited [50, 
137].  Most of these systems rely on small molecule detection, such as copper, 
phosphates, methionine or aromatic amino acids [48, 138-140] using native, trans-
activing factors that result in relatively weak levels of inducibility.  The stand-out 
anomaly both with respect to carbon source inducible nature and strength of induction is 
the galactose system [141].  Another inducible system of interest is the ethanol inducible 
TPS1 system, which has been used to induce flocculation in the industrial yeast strain 
ZLH01 and achieve cost-effective cell separation [142].  While it is possible to use these 
endogenous systems for unique applications including quorum sensing and metabolic 
control [143], there is still a lack of parts to enable complex synthetic circuits in yeast.  
 
One particularly attractive and potent endogenous inducible system in S. 
cerevisiae that has been studied throughout the years is aromatic amino acid induction 
and regulation [48, 144, 145].  The first step in aromatic amino acid catabolism, the 
aromatic amino acid transferase II protein encoded by ARO9, is under significant 
regulation.  In particular, the ARO9 (as well as ARO10) gene is activated by GATA and 
Aro80p transcription factors in response to nitrogen limitation as well as exogenous 
aromatic amino acids [144].  This activating function in conjunction with knowledge of 
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the Aro80p binding site has been recently used in a synthetic context to induce gene 
expression  [146].  However, these systems have not been fully engineered for maximal 
expression and inducibility through trans-factor engineering.  Here, we present the 
engineering of the Aro80p trans-activing factor for enhanced expression and inducibility.  
We demonstrate that an identified mutant factor can be used in conjunction with cis-
acting element engineering to create ultra-strong promoters with activity nearly 2-fold 
higher than the strong, constitutive TDH3 (GPD) promoter.  Finally, we demonstrate the 
capacity to utilize this factor in a configuration that is capable of generating staged 
outputs with up to 6-fold, 12-fold or 14-fold induction from the “off” state as a function 
of inputs.  Collectively, these results demonstrate the capacity to rewire yeast promoters 
through the modulation of both cis-acting element and trans-acting factor components. 
 
3.3 RESULTS AND DISCUSSION  
3.3.1 Initial synthetic promoter construction using an aromatic inducible 
transcription factor 
Initially, we sought out to engineer both minimally-sufficient and hybrid cis-
elements to establish a baseline aromatic amino acid inducible promoter system for yeast.  
The design for this promoter element was based on the native ARO9 promoter that has 
been previously demonstrated to have aromatic amino acid (esp. tryptophan) inducibiliy 
[48].  First, to generate a native design, a 355 base pair promoter was amplified from the 
genome corresponding to the previously reported structure with the additional truncation 
of four potentially confounding Pho4p binding sites [147, 148].  This native promoter 
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was cloned into a basic yeast vector in front of the yECitrine fluorescent protein (in a low 
copy centromeric p416 plasmid to form the “ARO9wt-YFP” construct)  [122].  This 
wild-type promoter construct showed slight constitutive expression in basic minimal 
media and over 2-fold induction upon exposure to 500 mg/L tryptophan (Figure 3.1A).  
Thus, this endogenous element could serve as a baseline for aromatic acid inducibility. 
Next, to enable a more minimal and hybrid approach, we dissected the ARO9 
promoter to extract a more minimally sufficient UASaro element.  The UASaro element 
previously described [48] failed to provide any activity when cloned upstream of a 
LeuMin core, therefore this putative UASaro element was expanded to include 56 bp 5’ 
and 24 bp 3’ of the Aro80p binding site.  The 5’ flanking region begins after a putative 
URS1 element, while the 3’ flanking region ends before a TATA box like sequence.  
When this enlarged UAS element was linked with the LeuMin core promoter, we 
designed a functional 249 bp synthetic promoter.  The resulting construct was cloned into 
a similar plasmid as described above to form the “1x UASaro -YFP” construct.  In similar 
fashion to the endogenous promoter, transformed yeast cells were evaluated by flow 
cytometry at mid-with and without a spiked of 500mg/L L-tryptophan to demonstrate 
Aro80p based activation.  Both the native and the synthetic promoter demonstrated leaky 
constitutive expression (likely due to endogenous aromatic amino acid levels) but had 
inducible characteristics upon exposure to culture media spiked with 500 mg/L L-
tryptophan (Figure 3.1A).  The basal expression of the hybrid promoter construct was 
significantly higher than that of the native promoter sequence. This difference could be 
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due to additional repressor binding sites not being captured within the isolated UASaro 
element. The tight regulation of the native ARO9 promoter is expected as this element 
would be under strong evolutionary pressure to prevent constitutive catabolism of 
aromatic amino acids leading to a futile cycle. 
 
Figure 3.1 Developing a tryptophan sensitive hybrid promoter.   
(A) The 355bp “wild-type” ARO9 promoter and 1xUASaro hybrid promoters are 
evaluated by flow cytometry following subculture into CSM and CSM containing 
500mg/L of tryptophan.  Both promoters demonstrate leaky, constitutive expression with 
inducible traits with upward of 2-fold induction upon tryptophan addition.  The 
1xUASaro hybrid promoter exhibited higher constitutive expression while maintaining 
modest induction capacity.  (B)  Promoter constructs (synthetic designs with 1 and 4x 
UASaro elements and the endogenous control) were tested alongside a plasmid 
containing the aro80wt gene under control of the strong TEF promoter.  Each construct 
maintained a roughly 2.5 fold inducible range while hybrid engineering increased the net 
expression from the constructs.  The BY4741- plasmid control is included to demonstrate 
the relative level of background auto-fluorescence and samples for (A) and (B) were 
analyzed by flow cytometry on the separate days under the same conditions.  Error bars 




3.3.2 Hybrid promoter engineering to refine the aromatic amino acid response 
We have previously demonstrated that a hybrid promote reengineering approach 
can increase the overall activity of promoters through the modification of cis-acting 
elements [62, 66].  In this regard, we sought to demonstrate that additional copies of the 
above identified UASaro can amplify the transcriptional output of the synthetic promoter.  
To do this, we increased the number of copies of UASaro elements from 1x to 4x 
upstream of the core promoter.  Furthermore, as endogenous Aro80p pools might limit 
the transcriptional output from these hybrid promoters, we overexpressed the native 
ARO80 gene in trans along with these constructs.  The resulting inducible capacity of 
these three systems (the wild-type ARO9 promoter and the 1x and 4x hybrid constructs) 
was evaluated via flow cytometry using a range of tryptophan concentrations (Figure 
3.1B).  These results demonstrate that indeed a hybrid promoter engineering approach 
can amplify the transcriptional output of these promoters.  In each of the cases, a 2.5-fold 
inducibility level was observed with and without exogenous tryptophan whereas the 
magnitude of expression followed the trend of ARO9 < 1x UASaro < 4x UASaro.  As a 
result, it is possible to tune the output of this inducible promoter system via a hybrid 
promoter engineering approach. 
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3.3.3 Establishing a mutant Aro80p factor that can alter promoter response 
Next, we sought to modulate the trans-acting factor for this promoter element 
(namely Aro80p) as a means of altering promoter activity.  Specifically, the goal was to 
modulate both the constitutive and inducible traits of this promoter via protein 
engineering.  More specifically, we wished to retain some inducible traits in the 
promoter, but at the same time, enabling a much stronger constitutive response.  To 
accomplish this, we used error-prone PCR to generate a mutant library of aro80 genes.  
To screen for altered function, we utilized an aro80Δ cell line that avoids interaction with 
native ARO80 expression and function.  The aro80 mutant library was transformed into 
the aro80Δ cell line expressing p416-4xLeuMin-YFP and enriched via FACS (FACSaria) 
to identified improved mutants.  In this case, we opted to sort the top 1% of fluorescent 
cells in the presence of D-tryptophan to block activation domains.   Out of many colonies 
evaluated, one particular set of mutations (specifically I551S and S675T) was isolated 
from a variant that yielded high constitutive and inducible activation of the 4x UASaro 
promoter (Figure 3.2).  The particular variant, aro80I551S,S675T is hereafter referred to as 
“aro80mut”. 
To identify the causative mutation(s) responsible for aro80mut function, we 
individually reverted the two point mutations and evaluated function of the resulting 
single mutation transcription factors.  Figure 3.2 demonstrates that the dominant 
mutation responsible for the function of aro80mut was I551S.  Specifically, reverting the 
mutation at residue 675 still retained function whereas reversion of the mutation at 
residue 551 reverted functions to levels near that of the wild-type Aro80p.  Collectively, 
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we have demonstrated the capability of identifying a mutant version of Aro80p capable 
of increasing constitutive expression levels by over 5-fold compared to the wild-type 
version, while maintaining an inducible response to exogenous amino acids.  It is 
possible to use this new mutant in conjunction with cis-acting element promoter 
engineering to develop new synthetic circuits as described in the sections below.  
 
Figure 3.2 Isolating causative mutations in the aro80 mutant.  
A single residue reversion assay was conducted to identify the causative mutation(s) 
leading to aro80 function.  The aro80mut, two revertants, ARO80 wt and a blank plasmid 
were expressed in conjunction with the 4xUASaro-YFP and ARO9wt-YFP plasmids and 
measured in CSM and CSM containing 500mg/L of tryptophan.  All samples were 
analyzed by flow cytometry on the same day under the same conditions.  Error bars 
represent standard deviations across biological replicates. 
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3.3.4 Development of an ultra-strong promoter via aro80mut 
To demonstrate the power of coupling cis-acting element and trans-acting factor 
engineering to alter promoter function, we first use this factor to drive high level, 
constitutive gene expression.  To do so, we establish a simple “amplifier” by expressing 
the aro80mut gene under the control of a strong constitutive promoter (in this case, the 
TEF promoter) and using the resulting protein to drive the expression of a hybrid 
promoter (Figure 3.3A).  Previous work has shown that the addition of UAS elements 
upstream of native promoters can significantly increase their net transcriptional output 
[62, 149]. The rationale being that the promoters are limited by transcription factor 
binding and that by increasing the presence of the enhancer elements, we increase the 
frequency of binding and therefore transcription.  In this case, we use our hybrid 
promoter engineering approach to place several UASaro elements (in this case, 4 to 5 
copies) upstream of several full-length, endogenous promoters (CYC1 and HXT7) a 
minimal promoter (LeuMin), and the synthetic, minimal core promoter CORE1 40.  In 
each of these cases, constitutive expression of the mutant aro80 factor greatly increased 
the net, constitutive expression from each of the promoters (Figure 3.4A).  For the case 
of our minimal core promoter, this amplification gain was up to 15-fold.  In several of the 
cases, the obtained expression in this circuit was greater than that of the TDH3 (GPD) 
promoter, arguably among the strongest, endogenous constitutive promoters for yeast.  
The strongest resulting hybrid promoter (the 5x- UASaro hybrid) exhibited up to 2-fold 
increase in yECitrine fluorescence compared with the TDH3 promoter and upwards of 
1.7-fold increase in mRNA output (Figure 3.4B).  Thus, these experiments demonstrate 
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that using an aro80mut can result in strong, constitutive expression of an output promoter 
leading to one of the strongest promoters available for S. cerevisiae.   
 
 
Figure 3.3 Synthetic circuit schematics.  
Schematics for the two circuits considered in this work are provided. (A) An amplifier 
was created through the use of the constitutive overexpression of aro80mut driving the 
activation of a hybrid promoter. (B) A Digital-to-Analog converter was created consisting 
of aro80mut under control of the GAL1 promoter driving activation of the hybrid 
promoters.  With this system, the output is modulated by two inputs (carbon source: 
glucose or galactose and exogenous tryptophan: low and high).  This expected output is 





Figure 3.4 Development of ultra-strong promoters via aro80mut.  
Using hybrid promoter engineering, tandem repeats of the UASaro were placed upstream 
of a variety of promoters. (A)  These plasmids were expressed within the aro80mut 
amplifier context presented in Figure 3A resulting in gene expression up to 15 fold higher 
with the hybrid constructs compared to the corresponding basal promoter (shown in 
lighter hues).  Some promoters exhibited up to 2-fold higher expression than GPD, one of 
the strongest promoters in yeast. All samples were analyzed by flow cytometry on the 
same day under the same conditions.  Error bars represent standard deviations across 
biological replicates. (B) Transcript levels were measured for three strains expressing 
amplifier circuits along with GPD-YFP as a benchmark.  All transcript values are 
reported relative to the BY-LeuMin-YFP-aro80mut strain.  The expression profiles match 
fluorescence data, with the 5xUASaro amplifier expression being roughly 1.7 fold that of 




3.3.5 Development of a promoter with staged output using the aro80mut  
As a second demonstration of the utility of coupling cis- and trans-acting factor 
engineering, we utilized the resulting aro80mut to achieve a staged, multi-output 
response in yeast.  A similar circuit has recently been demonstrated for E. coli whereby 
two digital (on/off) inputs result in an analog response, termed a “Digital-to-Analog 
converter” [150].  While the biological circuit is inherently noisier than its electronic 
counterpart, this term is employed here to be consistent with the literature  [150].  To 
demonstrate a similar circuit for yeast, we expressed the aro80mut gene under 
transcriptional control of the GAL1 promoter (Figure 3.3B).  This mutant factor was then 
used to drive the expression of three distinct hybrid promoter constructs.  Using this 
system, it is possible to modulate output via changes to the conditions of glucose vs. 
galactose and un-spiked vs spiked tryptophan.  In this regard, the glucose condition 
represents an “off” state, the tryptophan induction of endogenous, wild-type Aro80p 
represents a “Low1” intermediate state, galactose induction of aro80mut represents a 
“Low2” intermediate state and the tryptophan induction of both endogenous aro80wt and 
galactose induced aro80mut presents the final “High” state.  To test this function, the four 
experimental inputs were: glucose, glucose with 1g/L tryptophan, galactose, and 
galactose with 1g/L tryptophan.  Figure 3.5 demonstrates the realization of this 4-state 
promoter system.  For the case of the 5x-LeuMin, the fold expression over the “off” state 
was 6 fold higher with tryptophan, 12 fold with galactose and 14.6 fold with galactose 
and tryptophan.  This full induction resulted in fluorescence values roughly 50% of the 
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GAL1 promoter.  The 5xCYC circuit responded comparably with 3 fold, 6 fold and 
almost 8 fold activation for each of the various on states. 
Finally, by removing the activation provided by endogenous, wild-type Aro80p, it 
is possible to remove a potential state.  Specifically, by expressing this system in an 
aro80 deletion strain (Figure 3.5), the system can no longer be activated solely by 
tryptophan and thus the only states observed are “Off”, “Low2” and “High”.  
Collectively, these two applications demonstrate the utility of using a mutant trans-acting 





Figure 3.5 Demonstrating a staged-output promoter system.   
A so-called “Digital-to-Analog converter circuit” (Figure 3B) was generated with the 
aro80mut gene under transcriptional control of the GAL1 promoter and used to drive the 
expression of three hybrid promoter constructs.  Resulting expression of the 5x-UASaro 
circuit is 6 fold higher with tryptophan over the “off” state due to the activation of the 
endogenous ARO80p, 12 fold higher with galactose inducing expression of aro80mut and 
14.6 fold with galactose and tryptophan induced.  The 5xUASaro-CYC construct 
responded comparably with 3 fold, 6 fold and 8 fold activation.  These outputs compare 
with the truth table depicted in Figure 3B.  These constructs are expressed in an aro80Δ 
background to remove one of the states.  CYC-YFP and TEF-YFP are included in the 
circuit context as endogenous controls and GAL1-YFP is expressed without the circuit as 
an expression benchmark. All samples were analyzed by flow cytometry on the same day 




3.4 CONCLUDING REMARKS  
In this chapter, we demonstrate the power of combining cis-acting element 
engineering with mutant trans-acting factors to engineer yeast promoters.  Specifically, 
we first develop an inducible, hybrid promoter based on the upstream region of the ARO9 
promoter.  Next, we isolate a mutant aro80 protein that can afford increased constitutive 
expression while retaining inducible traits.  Finally, we utilize this factor to generate 
ultra-strong promoters and to establish a promoter capable of staged-outputs.  In the 
former case, we demonstrate promoters with transcriptional output roughly 2-fold higher 
(based on both fluorescence and mRNA) compared to the TDH3 (GPD) promoter.  Thus, 
this promoter system is one of the strongest yeast expression systems reported to date.  In 
the latter case, we enabled a system with activation levels of 6-fold, 12-fold or 14-fold of 
the “off” state as a function of circuit input.  Collectively, this chapter demonstrates the 
utility of both engineering endogenous transcription factors with hybrid promoter 
engineering approaches.  The ability to expand this paradigm for other endogenous or 
previously demonstrated heterologous systems provides great promise for expanding the 





Plasmid Source or Assembly Method Primers 





    Rev: 
GCTCTAGAtgagtcgatgagagagtgtaatt 
p416-LeuMin-yECitrine  [62] n/a 
p416-1xUASaro-LeuMin-
yECitrine  













    Rev: cccAAGCTTatgtttcctaccccaatgat 




    Rev: 
ccTTAATTAAatgtttcctaccccaatgat 




    Rev: 
ttGGCGCGCCatgtttcctaccccaatgat 
Table 3.1: continued next page. 
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p415-TEF ATCC n/a 
p415-TEF-aro80 Homlogous Recombination aro80 Fwd: 
gctcattagaaagaaagcatagcaatctaatctaagtt
tATGTCTGCTAAGAAAAGGCC 
    aro80 Rev: 
ggcgtgaatgtaagcgtgacataactaatTTATT
TACGCGTTATTGGCC 
    Vector Rev: 
AAACTTAGATTAGATTCGTATGC
TTTCTTTC 
    Vector Fwd: 
ATTAGTTATGTCACGCTTACATT
CACG 









Quick Change Kit Fwd: 
GCAAAAATAGAGATCATTCGAA
TCCT 














    Rev: 
TCTGTATGCTAATTCCACATAC 
p416-CYC-yECitrine  [62] n/a 
p416-HXT7-yECitrine  [130] n/a 
p416-GPD-yECitrine  [62] n/a 
p416-TEF-yECitrine  [64] n/a 












Gibson Assembly 5xUASaro Fwd: 
cctcactaaagggaacaaaagctggagctcGGA
TCCCGGCCGTAGATAATAAC 
Table 3.1: continued next page. 
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    Vector Rev: 
ttcctttgttattatctacggccgGGATCCGAG
CTCCAGCTTTTGTTCC 















Restriction Cloning with 
BamHI/PmeI 
n/a 
p415-Gal1-aro80-mut Gibson Assembly pGAL1 Fwd: 
cctcactaaagggaacaaaagctggagctcAGT
ACGGATTAGAAGCCGCCG 




Table 3.1: continued next page. 
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p416-GAL1-yECitrine [62] n/a 
Table 3.1 Plasmids used in this chapter.  
A list of plasmids generated and used in this chapter. 
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Strain Name Plasmid(s) 
BY4741  N/A 
BY-ARO9wt-YFP p416-ARO9wt-yECitrine  
BY-1xUASaro-YFP p416-1xUASaro-LeuMin-yECitrine  
BY-ARO9wt-YFP-aro80wt p416-ARO9wt-yECitrine , p415-TEF-aro80 
BY-1xUASaro-YFP-aro80wt p416-1xUASaro-LeuMin-yECitrine , p415-TEF-aro80 
BY-4xUASaro-YFP-aro80wt p416-4xUASaro-LeuMin-yECitrine , p415-TEF-aro80 
BY4741Δaro80 N/A 
aro80Δ-4xUASaro-YFP p416-4xUASaro-LeuMin-yECitrine  
BY-4xUASaro-YFP-Empty Vector p416-4xUASaro-LeuMin-yECitrine , p415-TEF 
BY-4xUASaro-YFP-aro80wt p416-4xUASaro-LeuMin-yECitrine, p415-TEF-aro80 







BY-ARO9wt-YFP-Empty Vector p416-ARO9wt-yECitrine , p415-TEF 
BY-ARO9wt-YFP-aro80wt p416-ARO9wt-yECitrine , p415-TEF-aro80 
BY-ARO9wt-YFP-aro80mut p416-ARO9wt-yECitrine , p415-TEF-aro80-mut 
BY-ARO9wt-YFP-aro80mut-S551I p416-ARO9wt-yECitrine , p415-TEF-aro80-mut-S551I 
BY-ARO9wt-YFP-aro80mut-T675S p416-ARO9wt-yECitrine , p415-TEF-aro80-mut-T675S 
BY-CYC-YFP-aro80mut p416-CYC-yECitrine, p415-TEF-aro80-mut 
BY-5xUASaro-CYC-YFP-aro80mut p416-5xUASaro-CYC1-yECitrine, p415-TEF-aro80-mut 
Table 3.2: continued next page. 
 69 
BY-CORE1-YFP-aro80mut p416-5xUASaro-CYC1-yECitrine, p415-TEF-aro80-mut 
BY-5xUASaro-CORE1-YFP-aro80mut p416-5xUASaro-CYC1-yECitrine, p415-TEF-aro80-mut 
BY-HXT7-YFP-aro80mut p416-HXT7-yECitrine , p415-TEF-aro80-mut 
BY-5xUASaro-HXT7-YFP-aro80mut p416-5xUASaro-HXT7-yECitrine , p415-TEF-aro80-mut 




BY-5xUASaro-YFP-aro80mut p416-5xUASaro-LeuMin-yECitrine, p415-TEF-aro80-mut 
BY-TEF-YFP-aro80mut p416-TEF-yECitrine , p415-TEF-aro80-mut 
BY-GPD-YFP p416-GPD-yECitrine  
BY-5xUASaro-CYC-YFP-GAL1-
aro80mut p416-5xUASaro-CYC1-yECitrine, p415-Gal1-aro80-mut 
BY-4xUASaro-YFP-GAL1-aro80mut p416-4xUASaro-LeuMin-yECitrine,p415-Gal1-aro80-mut 
BY-5xUASaro-YFP-GAL1-aro80mut p416-5xUASaro-LeuMin-yECitrine, p415-Gal1-aro80-mut 
aro80Δ-5xUASaro-CYC-YFP-GAL1-
aro80mut p416-5xUASaro-CYC1-yECitrine, p415-Gal1-aro80-mut 
aro80Δ-5xUASaro-YFP-GAL1-
aro80mut p416-5xUASaro-LeuMin-yECitrine, p415-Gal1-aro80-mut 
BY-CYC-YFP-GAL1-aro80mut p416-CYC-yECitrine, p415-Gal1-aro80-mut 
BY-TEF-YFP-GAL1-aro80mut p416-TEF-yECitrine ,p415-Gal1-aro80-mut 
BY-GAL1-YFP p416-GAL1-yECitrine 
 
Table 3.2 Yeast strains used in this chapter.  
Yeast strains used in this chapter and the plasmids which they maintain.  
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Chapter 4:  Biosensor Directed Evolution for Muconic Acid Production 
in Saccharomyces cerevisiae 
4.1 CHAPTER SUMMARY 
 
Having developed the ARO9 cis-acting elements and ARO80 trans-acting factor 
components to facilitate improvements in gene expression, we next employed this as a 
biosensor to further develop muconic acid production in S. cerevisiae. To further increase 
muconic acid production in this host with industrially relevant titers, we employed an 
adaptive laboratory evolution (ALE) strategy to complement rational metabolic 
engineering.  ALE allows for the selection of global phenotypes without prior knowledge 
of an organism’s metabolism. Isolating improved strains relies on the availability of an 
effective selection strategy specific for the desired phenotype. In this chapter, we adapted 
a biosensor device developed in the previous chapter which is sensitive to the 
endogenous aromatic amino acid production (AAA) in S. cerevisiae using a hybrid 
promoter approach, and used this biosensor to augment an anti-metabolite ALE scheme. 
Following two iterations of mutation and selection in our ALE scheme, we isolated 
strains of S. cerevisiae that are capable of 2-fold AAA production relative to our 
previously engineered strain and 10-fold that of wild-type S. cerevisiae. Having 
successfully selected for improvements in flux through the shikimate pathway, we then 




The resulting four strains represent a combination of rational metabolic 
engineering and evolutionary adaptation. To demonstrate the improvements in flux 
gained from ALE, we expressed the composite muconic acid pathway we have 
previously demonstrated, and the ALE isolated strains were capable of three fold the 
pathway production compared to our previously engineered strain. We next desired to 
rationally reroute flux into the composite pathway through a truncation of the shikimate 
pathway. We truncated the penta-functional ARO1 protein and expressed it resulting in 
strains capable of 7.5 fold output from the composite pathway. Our final step in strain 
engineering was the expression of the endogenous PCA decarboxylase, scPAD1, which 
resulted in a strain capable of over 550mg/L muconic acid production in flasks and 1.94 
g/L in a fed-batch bioreactor. This represents the highest production of muconic acid in S. 




In chapter 3, we employed a hybrid approach to develop promoters which were 
inducible to AAA. Now, we will employ the ARO9 derived hybrid promoters as 
biosensors to further improve S. cerevisiae strains for muconic acid production through 
ALE. In chapter 2, the production of muconic acid in S. cerevisiae resulted in titers of 
141 mg/L [1] and represented traditional metabolic engineering work of composite 
pathway development, screening heterologous enzymes for function in the desired 
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production host, and optimizing carbon flux into the composite pathway utilizing flux 
balance analysis. Other groups have demonstrated further improvements in titer resulting 
from protein engineering which eliminated flux downstream of the composite pathway 
and subsequent bioreactor scale-up facilitating dissolved oxygen (DO) control to improve 
enzymatic activity of the rate limiting step, resulting in titers of 559.5 mg/L [24]. Other 
work by Horwitz and coworkers demonstrated Cas9 mediated engineering to facilitate 
alternative shikimate pathway utilization by importing the heterologous pathway from E. 
coli, ostensibly for the production of muconic acid, however they did not report titers of 
muconic acid from glucose [17]. While there has been significant interest in the 
development of S. cerevisiae for the production of secondary metabolites derived from 
the shikimate pathway, it faces a number of difficulties including low precursor 
availability and high degrees of flux control exhibited by pathway enzymes and 
regulatory proteins [100, 151, 152]. These difficulties have previously limited titers from 
glucose to the level of 102 mg/L for naringenin [153], 141 and 559.5mg/L for muconic 
acid [1, 24] and only through the replacement of yeast metabolism with parts from E. coli 
were groups able to increase titers of to 1.93g/L for p-coumaric acid [152]. To address 
these limitations, we sought to employ an adaptive evolution approach in order to 
improve titers beyond current limits.  
The process of natural evolution leads to the selection of beneficial traits over 
long periods of time as organisms adapt to their surrounding environment [154]. Two of 
the defining characteristics of an ALE scheme are the generation of sequence diversity 
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and the selection mechanism. Sequence diversity can be achieved through chemical 
mutagenesis or through study over long evolutionary time spans while selection of the 
desired phenotype is typically achieved by selection under specific growth conditions 
leading to an enrichment of a subpopulation capable of improved growth rates [22, 39].  
While improved growth rates continue to be the core mechanism of selection, recent 
evolutionary strategies exist which exploit a chemical feature of the desired product to 
facilitate selection for improved production of a compound of interest [12, 155] or the 
presence of an anti-metabolite to aid selection for improvements in production of a 
specific product [156, 157]. These anti-metabolites present a disruptive metabolic 
pressure on the cells which can be overcome through mutations resulting in higher 
concentrations of the metabolite of interest. As whole cell biosensors are becoming more 
commonly available [21, 158], these resources provide an opportunity to expand the 
scope of selectable phenotypes for strain improvement through ALE.   
Biosensors allow for tying intracellular product formation with an output that can 
be readily screened, providing a way of screening beneficial mutations either in high 
throughput assays with a reporter or selection through resistance. Recently, a fluorescent 
biosensor was utilized in an ALE scheme to improve L-Valine production in C. 
glutamicum [44] with flow cytometry used to facilitate selection. One of the advantages 
of traditional ALE is the use of growth based phenotypes to allow selection rather than 
relying on the limited throughput of screening, which a biosensor be cleverly 
implemented to provide. Previously, the growth coupled screening using a biosensor in S. 
 74 
cerevisiae was performed using the glmS riboswitch to screen enzymes to produce N-
acetyl glucosamine [43] and L-lysine riboswitch in E. coli [159]. This chapter represents 
the first application of a transcription factor based biosensor for ALE in S. cerevisiae and 
the first coupling of a biosensor with an anti-metabolite strategy. A major advantage of 
this biosensor directed evolution scheme is that it provides a generalizable strategy 
opening up new chemical products for growth based selection. 
One implementation of a biosensor is the ARO9 promoter, previously used to 
establish hybrid promoters of varying strength and inducibility in chapter 3.  In this 
chapter, we demonstrate how biosensor-mediated ALE combined with local pathway 
optimization can further muconic acid production in S. cerevisiae. We demonstrate the 
usage of an ARO9 based biosensor and application for selection in an ALE experiment in 
order to screen for genome wide changes that can facilitate improvements AAA as a 
surrogate for improvements in muconic acid production. Through this ALE, we 
developed strains capable of 2-fold higher AAA production, 3-fold higher output from 
the muconic acid composite pathway and following some pathway engineering and 
bioreactor scale up resulted in 1.94 g/L muconic acid production which is the highest 
production of muconic acid in yeast as well as one of the highest of a shikimate pathway 
derivative.   
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4.3 RESULTS AND DISCUSSION  
4.3.1 Adaptation of Biosensor for Adaptive Laboratory Evolution   
 
Previous approaches have focused on only rational engineering targets to improve 
strains for production of shikimate derivatives since a high-throughput detection was 
limiting.  To enable high-throughput strain engineering (such as through ALE), we 
required a methodology to screen or select based on muconic acid level.  For this chapter, 
we hypothesized that AAA production could serve as a surrogate to muconic acid.  In the 
prior chapter, we built hybrid promoters through tandem insertions of the UASaro 
element upstream of a minimal core promoter. Here, we sought to adapt this biosensor to 
enable ALE. 
ARO9 based biosensors have been shown to be induced through exogenous 
feeding of AAA [2, 48, 147], however they have not been previously used to distinguish 
differences in endogenously produced AAA. To demonstrate the biosensors capacity to 
evaluate these differences, we sought to test the biosensor in BY4741, wild-type (WT) 
yeast and the strain previously developed for muconic acid production containing the 
aro3, aro4 and zwf1 genes deleted and the feedback resistant aro4k229l gene integrated 
(hereafter referred to as ENG). In order to use the biosensor to improve strains for 
muconic acid production beyond their currently levels, we need to retain all of the 
beneficial improvements provided by the ENG strain and enable selection capacity 
beyond the current ENG production level. This requires differentiating WT from ENG 
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and demonstrating that the biosensor can be further induced through the presence of 
exogenous AAA.  
To test this, we transformed the biosensor plasmid p416-1xUASaro-Leumin-Yecit 
into the ENG and BY4741 strains and screened with flow cytometry in Complete 
Synthetic Media (CSM) CSM and CSM with additional AAA. As shown in Figure 4.1, 
the ARO9 based biosensor provides a holistic induction based on the intra and extra-
cellular AAA concentration, with the different trends presented by BY4741 and ENG 
potentially due to differences in basal production. Using the biosensor, the ENG is shown 
to possess a higher basal expression level and the biosensor can be further induced using 
exogenous amino acid supplementation demonstrating that it could be used to select for 
further improvements in endogenous AAA production if used to drive a selectable 
condition. Having demonstrated that the biosensor could be successfully used to screen 
improvements in our previously engineered strain, we next turned to converting the 




Figure 4.1 Biosensor Inducible Capacity. 
The ability of the biosensor to detect differences in endogenous AAA production as well 
as further inducible capacity is measured. The p416-1xUASaro-Leumin biosensor is 
tested in BY4741, wild-type (WT) yeast and the strain previously developed for muconic 
acid production (ENG).  All samples were analyzed by flow cytometry on the separate 




4.3.2 Selective Conditions Analyzed  
 
ALE allows for the selection of mutations which provide a growth benefit in the 
experimental conditions. Biosensors provide a way of screening beneficial mutations in a 
high throughput a reporter for screening or selection through resistance. Now that we 
have demonstrated the ability to detect improvements in AAA production in excess of 
our previously engineered strain, we used this AAA inducible hybrid promoter to drive 
expression of the KanNeo gene isolated from the piTY vector [101]. This gene confers 
weak antibiotic resistance to geneticin (G418) in yeast. The poor resistance conferred by 
this gene had previously been used to identify tandem-integrations. To create an 
inducible antibiotic resistance phenotype, we replaced the yECitrine CDS of the p416-
4xUASaro-Leumin-Yecit plasmid with the KanNeo G418 resistance gene from the piTY 
vector to generate the biosensor plasmid p416-4xUASaro-Leumin-KanNeo. This vector 
was transformed into BY4741 and its growth rate was screened versus a BY4741 
expressing a generic yECitrine reporter plasmid to assay the inducible resistance 
conferred by the KanNeo biosensor as well as the selection potential of anti-metabolites. 
By employing multiple selective conditions, both biosensor and anti-metabolites, we 
hope to ensure that the ALE selection pressure results in the selection of improvements in 
AAA production rather than improvements in biosensor performance. 
 Using growth rate under selection as a guideline, we tested a number of media 
conditions to identify the antibiotic and anti-metabolite concentrations which would 
ensure optimal selection. Figure 4.2 demonstrates that the 200mg/L G418 slightly 
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reduces growth rate in both reporter and biosensor strains, but 400mg/L completely 
abolishes the growth in the control and moderately reduces that of the strain expressing 
the KanNeo biosensor. Next, we demonstrate that this reduction in growth rate deficit can 
be alleviated by feeding exogenous AAA to induce the biosensor as compared to our 
generic reporter plasmid. Finally we tested AAA anti-metabolites previously described in 
the literature to see if these amino acid analogs could inhibit the growth rate further for 
use in conjunction with the biosensor. We selected the AAA analogs 4-
Fluorophenylalanine (4FP) and 3,4-DL-Dihydroxyphenylalanine (DL-DOPA). These had 
previously been shown to been toxic and that toxicity could be alleviated through feeding 
of the natural AAA [160, 161].  The analogs were included this in the media with 
400mg/L G418 and the biosensor and control screened for growth, resulting in further 




Figure 4.2 Evaluation of media conditions for ALE selection.  
Growth rate is measured for WT yeast strains expression 4xUASaro-KanNeo biosensor 
and control plasmid. The inducible capacity of the 4xUASaro-KanNeo biosensor is 
demonstrated by recovery of growth rate using exogenous aromatic amino acids as 
compared to control strain. Further reduction in growth rate is achieved using 3,4 
Dihydroxyphenylalanine (5mM) and 4-Fluorophenylalanine (5mM). Error bars represent 
standard deviations across technical replicates.  
 




While natural mutation rates have been commonly employed in ALE schemes, 
chemical mutagenesis can greatly speed up the rate of mutation and arrive at desirable 
evolutionary outcomes quickly with appropriate screening criteria [162]. We used 
sequential subculturing, transferring a fraction of the population into fresh media to allow 
improvements in growth rate to be selected for while allowing adaptation to increased 
concentrations of G418 antibiotic and 4FP.  
Using EMS mutagenesis as described previously [163], the ENG strain expressing 
p416-4xUASaro-KanNeo plasmid was mutagenized resulting in two mutagenenized 
populations (1x99+% kill and 2x99+% kill) and one unmutagenenized control. This was 
done in duplicate resulting in six populations which were subcultured at stationary phase 
into media containing successively greater concentrations of G418 (antibiotic) and 4FP 
(anti-metabolite). The overall growth trajectory of these six populations (labeled Pop 1-6) 
is reported in Figure 4.3. After 6 rounds of subculturing over 750 hours, the 
unmutagenized control populations were unable to grow in the selective media 
conditions, while the mutagenized populations continued to grow in 1000 mg/L G418 
and 2mM 4-FP, suggesting that we had reached a point of selection where we believed 
that a fraction of cells within the successfully growing populations could be producing 





Figure 4.3 Adaptive Laboratory Evolution Log 
 Following EMS mutagenesis, the six populations (1x and 2x 99% kills and no-EMS 
control in duplicate) were subcultured in the presence of increasing concentrations of 
G418 and 4-Fluorophenylalanine. Pop1 and 4 represent 1x 99% kills, while 2 and 4 
represent 2x 99% kills and  3 and 6 represent no-EMS respectively.  Following 750 hours 




To confirm that our ALE was resulting in the selection of a population of 
improved AAA producing strains, we plated and isolated colonies from the populations at 
750 hours. These colonies were labeled according to the population they were isolated 
from (i.e. ALE1.01 was the first isolate from Population 1, while ALE 5.02 was the 
second isolate from Population 5). Colonies were inoculated from plates into CSM and 
the tyrosine from the supernatant was directly quantified with a plate based tyrosine 
quantification method utilizing nitrosonapthol- derivatization and compared to the ENG 
strain as a control [164] presented in Figure 4.4.  We selected ALE-1.01, ALE-2.08 and 
ALE-5.01 to generate a second round of diversity through EMS. We cleared the plasmids 
with 5-FOA to confirm that the plasmids had not integrated. We then retransformed in 
the p416-4xUASaro-KanNeo vector and repeated the EMS mutagenesis to generate 9 
new populations. The 1x and 2x 99% kills or no-EMS controls represented by 1, 2 and 0 
in the final digit of the population name.  (i.e. ALE1.01.1 was the 1x 99% kill derived 
from ALE1.01, while Pop-5.01.2 was the 2x 99% kill derived from ALE 5.01). After 575 
hours, selection between high performing populations and low was achieved and the 
AAA production of individual isolates was quantified. 
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Figure 4.4 Tyrosine Quantification  
Tyrosine production of all ALE strains and controls were assayed using the first 
nitrosonapthol chemical derivatization described in Chapter 5.4.6 with a high throughput 
plate reader assay and ENG strain included as a control. All strains were assayed at the 
same time under the same conditions.  The red bars represent the three strains selected for 
the second round of EMS and ALE. Error bars represent standard deviations across 
biological replicates. The dotted line represents the mean production of the ENG strain.  
 
We wanted to ensure that this second round would result in improvements, so we 
started the selection at 1000 mg/L G418 and 1mM 4-FP and over the course of selection, 
the 4FP concentration was increased to 7.5mM as demonstrated in Figure 4.5. This 
represents a significant improvement in survival over the first round, which failed to 
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grow after being selected in 1000 mg/L G418 and 2mM 4-FP. After we reached a 
threshold where differential growth rates were observed between populations, we 
repeated the process of isolating individual strains from the selected populations. 
Tyrosine quantification was performed with CSM media containing 2% as well as 4% 
glucose in the media. The CSM with 4% glucose was selected to test with as it closer 
mimics the media conditions used to cultivate MuA12 for muconic acid production 





Figure 4.5 Adaptive Laboratory Evolution  Log.  
Following EMS mutagenesis of the top three strains isolated from the first round of ALE, 
the 9 populations were subcultured in the presence of 1g/L G418 and increasing 
concentrations of 4-Fluorophenylalanine. The populations which experienced 1x and 2x 
99% kills or no-EMS controls are represented by 1, 2 and 0 in the final digit of the 
population name.  After 575 hours, selection between high performing populations and 




Figure 4.6 Tyrosine Quantification  
Tyrosine production of all ALE strains and controls were assayed using the second 
nitrosonapthol chemical derivatization described in Chapter 5.4.6 with a high throughput 
plate reader assay and ENG strain included as a control. All strains were assayed at the 
same time under the same conditions.  The red bars represent the two of the four strains 
selected for the transformation with the composite pathway. Error bars represent standard 





Figure 4.7 Tyrosine Quantification  
Tyrosine production of all ALE strains and controls were assayed using the third 
nitrosonapthol chemical derivatization described in Chapter 5.4.6 with a high throughput 
plate reader assay and ENG strain included as a control. All strains were assayed at the 
same time under the same conditions.  The red bars represent the three of the four strains 
selected for transformation with the composite pathway. Error bars represent standard 
deviations across biological replicates. The dotted line represents the mean production of 






The tyrosine production described by these experiments clearly demonstrates that 
we had increased AAA production by 20-100%.  However, performance under the 
different conditions was variable. To improve the accuracy of our measurements we 
integrated our best practices for tyrosine quantification identified through our three 
rounds of method development and developed a fourth method. This allowed us to 
provide a more rigorous, in-depth analysis on what appeared to be some of our best 
strains by quantifying the tyrosine produced per OD unit in an overnight culture in media 
lacking amino acids or nitrogen supplementation, reported in Figure 4.8. To quickly 
detect the total AAA concentrations and provide a comprehensive picture of AAA 
production in these ALE strains, we decided utilize an ARO9 biosensor with a 
fluorescent reporter as a measurement of total AAA production. We selected the hybrid 
promoter 5xUASaro-CORE1 containing 5xUASaro elements upstream of the CORE1 
minimal synthetic core [2, 149], this was cloned into an EasyClone vector with yECitrine 
[165] to form p-XII-5xUASaro-CORE1. This vector was integrated into a neutral, high 
expression locus on Chromosome XII (Jensen 2014) in the seven ALE strains selected for 
a more in depth analysis were then assayed with flow cytometry.  As shown in Figure 
4.9, the ALE-2.08 and ALE-5.01 did indeed possess increased AAA production despite 
not seeing an improvement in tyrosine suggesting that mutations were accumulating in 
regions beneficial to the production of phenylalanine and/or tryptophan.  
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Figure 4.8 Tyrosine production from isolated ALE Strains.  
Tyrosine production of all ALE strains and controls were assayed using the fourth 
nitrosonapthol chemical derivatization described in Chapter 5.4.6 with a high throughput 
plate reader assay and ENG strain included as a control. All strains were assayed at the 
same time under the same conditions.  Error bars represent standard deviations across 




Figure 4.9 Fluorescent based biosensor quantification of Isolated ALE Strains.  
The overall AAA production of all ALE strains and controls was assayed will flow 
cytometry through an integrated biosensor expressing a fluorescent reporter. All strains 
were assayed at the same time under the same conditions.  Error bars represent standard 
deviations across biological replicates. 
 
Of the four isolated strains, ALE-1.02.1.03 seems to have lost any improvements 
in AAA production while ALE-1.02.2.01 is enriched in both tyrosine production and 
AAA as a whole, as measured by the biosensor. The improvement in AAA production 
presented by these strains confirms that our biosensor based selection platform was 
successful at isolating improvements in flux through the shikimate pathway. The next 
 92 
step is confirming that those improvements in flux correlate with improvements in 
production from our muconic acid composite pathway.   
4.3.4 Muconic Acid Production using Evolved Strains 
 
After the final strains have been confirmed for improved AAA flux, we sought to 
re-divert this flux toward our target muconic acid biosynthetic pathway.  To do so, we 
transformed with the muconic acid pathway into the ALE strains as well as the ENG base 
strain and their analyzed their production via HPLC. The muconic acid composite 
pathway draws off of 3-dehydroshikimate (3DHS) and consists of three enzymes 
previously described: a dehydroshikimate dehydratase from Podospora anserine 
(AROZpodo), protocatechuic acid decarboxylase from Enterobacter cloacae 
(ECL_01944opt), and catechol 1,2-dioxygenase from Candida albicans (caHQD2opt) 
[1].   
 We first constructed the integration vector PugM, to facilitate a single high-
strength integration of ECL_01944opt rather than relying on the inherent variation in 
tandem integrations used in our previous publication [1] and this high expression 
ECL_01944opt expression cassette was integrated into the TRP1 locus using the p416-
Gal-CAS9 [166]. After confirming integration, the following plasmids were sequentially 
transformed and confirmed through HPLC analysis: p425-AROZ-HQD2, p426-AROZ- 
ECL_01944opt and p413-TKL1 to create strains MuA-1.02.1.04, MuA-1.02.2.01, MuA-
5.01.1.02 and MuA-5.01.2.01. The production from this composite pathway in the ALE 
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strains and the previously engineered ENG strain (MuA13) is seen in Figure 4.10. This 
resulted in 3 fold composite pathway production relative to the ENG strain. This 
demonstrates the high AAA flux due to the ALE can be translated to improvements in 
output from our composite pathway. We next want to re-route flux away from the 
downstream products, AAA, and into the composite pathway and on to improving 




Figure 4.10 Composite Pathway Production of ALE Strains.  
The red bars represent ALE and control strains expressing the muconic acid composite 
pathway, while MuA13 represents ENG with similar pathway. Strains were cultured in 
the flask and total muconic acid pathway production was quantified by HPLC. Blue bars 
represent ALE strains with overexpression of the truncated ARO1t protein rerouting flux 
into the composite pathway. Error bars represent standard deviations across biological 
replicates. 
 
4.3.5 ARO1 Truncation 
 
To reroute carbon flux and divert this flux for producing muconic acid in the ALE 
strains, the flux needed to be rerouted to DHS and on to the composite pathway. The 
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Shikimate pathway in yeast is largely consolidated into one enzyme, the pentafuncational 
ARO1p. Other groups have addressed this either by cutting out ARO1p entirely and 
replacing it with the orthoganol pathway from E. coli [17], or through point mutations 
based on homology to E. coli proteins [24].  Here we propose an alternative strategy to 
engineering ARO1p to increase flux into 3DHS while limiting production of shikimic 
acid.  Previous homology modeling has identified the 1306-1588 residues of ARO1p to 
correspond with the shikimate dehydrogenase from E. coli, aroE. We proposed that by 
eliminating the enzymatic function of ARO1d through a truncation we would be able to 
direct flux directly into 3DHS at the expense of the downstream AAA. [99, 114] 
To identify a functional ARO1p truncation (ARO1t), we cloned mutant 
ARO1genes on plasmids and expressed them in aro1Δ alongside plasmids harboring the 
aroE gene from E. coli and screened for growth in media lacking AAA supplementation. 
While the simple truncation at codon 1305 failed to facilitate growth, the addition of 40 
amino acids of ARO1d facilitated growth in complementation with aroE. This suggests 
that these additional residues might be required to facilitate folding or other tasks 
essential to proper enzyme function. The functional ARO1t gene was then cloned into the 
p424 vector and transformed into ALE strains expressing the composite pathway.  The 
total pathway potential from these strains was then assayed and titers are reported in 
Figure 4.10, with MuA-5.01.1.02+ARO1t capable of producing roughly 1.5 g/L which is 




4.3.6 Composite Pathway Optimization 
 
With ARO1t introduced into the MuA-5.01.1.02 strain, MuA-5.01.1.02+ARO1t 
was able to produce over 1.5g/L from the composite pathway at the flask scale; however, 
this failed to correlate with high concentrations of muconic acid due to the poor 
enzymatic activity of AroY. Since our original work in this area, other groups have 
discussed the poor enzymatic activity of AroY and it remains a rate limiting step in 
muconic acid production [17, 24]. While Suastegui and coworkers demonstrated that this 
can be somewhat alleviated through control of oxygenation, we propose improving 
conversion through the use of an alternative PCA decarboxylase. Recent work identified 
scPAD1 as a functional decarboxylase in the S. cerevisiae genome, natively used to 
detoxify cinnamic acid [167]. To improve the conversion of PCA into muconic acid, we 
overexpressed the endogenous scPAD1 gene in the MuA-5.01.1.02+ARO1t  strain, 
resulting in significant improvements in throughput into the final muconic acid product 
with over 550mg/L muconic acid produced in shake flask and comparable to the titers 
Suastegui and coworkers report at the bioreactor scale. The resulting muconic acid titer is 
compared to the previously reported MuA12 strain in Figure 4.11 demonstrating the 
resulting four fold improvement in titer and yield provided by ALE and pathway 





Figure 4.11 Muconic Acid Production of MuA-5.01.1.02+ARO1t+scPAD1 Strain.  
Muconic acid production of the MuA-5.01.1.02+ARO1t+scPAD1 strain in flask 
compared against our previously reported muconic acid producing strain MuA12. MuA-
5.01.1.02+ARO1t+scPAD1 integrates our initial metabolic engineering work, ALE and 
final pathway rewiring through ARO1t and scPAD1 overexpression demonstrating a 4-






4.3.7 Bioreactor Fermentation 
 
While this strain produced the highest muconic acid to date in S. cerevisiae at 
flask scale, we desired to scale up the strain and demonstrate further improvements 
through control of pH, oxygenation and media formulation which have previously been 
shown to have great impact on final titer and yield of aromatic compounds [24, 152].  We 
selected CSM for our media formulation to closer replicate the media conditions which 
the ALE strains were evolved in. To closely mimic the microaerobic conditions 
previously shown to improve PCA decarboxylase activity, we maintained an SLPM of 
0.5 and maintained pH control at 5.0. The bioreactor fermentation was operated as a fed-
batch process with 3 media feedings throughout the run when the majority of glucose had 
been consumed. As shown in Figure 4.12, this process resulted in the production of 1.94 
g/L of muconic acid after 11 days representing the highest titer ever reported from 





Figure 4.12 Bioreactor Fermentation.  
Final muconic acid producing strain MuA-5.01.1.02+ARO1t+scPAD1 was cultured in 
bioreactor under batch conditions and PCA, Catechol, total muconic acid and glucose 
quantified. Three times throughout the run, as glucose was depleted additional media was 
spiked in, facilitating additional cell growth and production.  
 
4.4 CONCLUDING REMARKS 
 
This chapter represents a generic strategy which could be employed other 
biosensors to select for improved production of other metabolites. After our initial 
success expressing the muconic acid composite pathway and engineering the strain 
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through rational metabolic engineering, we then developed and employed an evolutionary 
strategy utilizing a biosensor to direct flux through the shikimate pathway employing 
AAA as a surrogate for muconic acid. Following two iterations of mutation and selection, 
we isolated strains of yeast capable of double the AAA production and three fold of the 
muconic acid pathway potential. We then performed some local pathway rewiring to 
ensure that our improvements flux through the shikimate pathway could be successfully 
re-routed into the composite pathway. 
To reduce flux downstream of 3DHS, we first engineered a truncated ARO1p 
which removed the shikimate dehydrogenase activity from the ARO1d domain. We then 
overexpressed this protein in our ALE strains expressing the muconic acid composite 
pathway resulting in strains capable of 7.5 fold output from the composite pathway and 
roughly doubling titers in our best performing strains. The final step in strain engineering 
was improving conversion from PCA to muconic acid through the expression of the 
endogenous PCA decarboxylase, scPAD1, which resulted in a strain capable of over 
550mg/L muconic acid production in shake flask and 1.94 g/L in fed-batch bioreactor 
with pH and DO control. This represents a nearly a 14-fold improvement over our 
previously reported strain, which is 4-fold of the highest reported titer of muconic acid in 
yeast. Through ALE and local pathway optimization we were able to accomplish the 
highest production of muconic acid in yeast, as well as one of the highest reporter titer of 




Plasmid Name  
Source of 
Assembly Method Primers 
p416-1xUASaro-Leumin-
yECitine  [2] n/a 
p416-4xUASaro-Leumin-




with XbaI and SalI Fwd: CTAGTCTAGAATGAGCCATATTCAACGG 
    Rev: ACGCGTCGACGAAAAACTCATCGAGCATCA 




with BamHI and 
PmeI Fwd: Ggggtaccgatcgcgtcagctgaagctt 
    Rev: CGGGATCCatcgcacgcattccgttg 
pug6 [123] n/a 
pugM-UASCLB–UASCIT–
UASTEF-GPD-








    
Promoter Fwd: gtatgctatacgaagttattaggtgatatc-
atagcttcaaaatgtttctactcctttttt 
    
Promoter Rev: ATTTATTGGGTTTTGCATactagttctaga-
atccgtcgaaactaagttctggtgttttaa 
    
ECL_01944opt Fwd: ttaaaacaccagaacttagtttcgacggat-
tctagaactagtATGCAAAACCCAATAAAT 












    




    




p416-Gal-Cas9-Trp1 [166] Trp1 gRNA Sequence: AGGAACTCTTGGTATTCTTG 






caHQD2opt [1] n/a 
p426-TEF-pa5_5120opt-
Tcyc-GPD-ECL_01944opt -












    
pa Cassette Rev: 
tgaaatggcgagtattgataatgataaactGAGCTCCAAATTAAAG
CCTTCG 
    
Ecl Cassette Fwd: 
gggacgctcgaaggctttaatttggagctcAGTTTATCATTATCAA
TACTCGCCATTTC 
    
Ecl Cassette Rev: 
cgcgtaatacgactcactatagggggtaccATTTTCAACATCGTA
TTTTCCGAAGCG 
p413-TEF-scTKL1 [1] n/a 
p415-TEF-ecAroE 
Restriction Cloning 
with SpeI and XhoI 
Fwd: 
GgactagtATGGAAACCTATGCTGTTTTTGGTAATC 
    Rev: CCGctcgagTCACGCGGACAATTCCTCC 
p413-TEF-ARO1t 
Restriction Cloning 
with SpeI and XhoI  Fwd: GGactagtATGGTGCAGTTAGCCAAAGTCC 






with SpeI and XhoI Fwd: GGactagtATGGTGCAGTTAGCCAAAGTCC 












scPAD1-IV BsaI Golden Gate 
Part vectors used: scPAD1 Entry vector, 
pYTK002,9,53,72,78,87,90,93 
Table 4.1: Plasmids used in this chapter.    
Plasmids were derived from those described in [122] with the exception of p-XII- 






Strain Name  Plasmids Genotype Features Source 
BY4741   






1xUASaro-yecitrine   
Mat a; his Δ1; 
leu2Δ0; met15Δ0; 
ura3Δ0 
(Leavitt, J. M., 
et al., 2016) 
ENG   




aro4k229l;  zwf1Δ 




















KanNeo p416-4xUASaro-Leumin-KanNeo  




aro4k229l;  zwf1Δ 
Plasmid 
Transformation 
Pop 1 p416-4xUASaro-Leumin-KanNeo    EMS 1x99% Kill 
Pop 2 p416-4xUASaro-Leumin-KanNeo    EMS 2x99% Kill 
Pop 3 p416-4xUASaro-Leumin-KanNeo    Control1 
Pop 4 p416-4xUASaro-Leumin-KanNeo    EMS 1x99% Kill 
Pop 5 p416-4xUASaro-Leumin-KanNeo    EMS 2x99% Kill 
Pop 6 p416-4xUASaro-Leumin-KanNeo    Control2 
ALE-1.01 p416-4xUASaro-Leumin-KanNeo      
ALE-1.02 p416-4xUASaro-Leumin-KanNeo      
ALE-1.03 p416-4xUASaro-Leumin-KanNeo      
ALE-2.01 p416-4xUASaro-Leumin-KanNeo      
ALE-2.02 p416-4xUASaro-Leumin-KanNeo      
ALE-2.03 p416-4xUASaro-Leumin-KanNeo      
ALE-2.04 p416-4xUASaro-Leumin-KanNeo      
ALE-2.05 p416-4xUASaro-Leumin-KanNeo      
ALE-2.06 p416-4xUASaro-Leumin-KanNeo      
Table 4.2: continued next page. 
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ALE-2.07 p416-4xUASaro-Leumin-KanNeo      
ALE-2.08 p416-4xUASaro-Leumin-KanNeo      
ALE-2.09 p416-4xUASaro-Leumin-KanNeo      
ALE-2.10 p416-4xUASaro-Leumin-KanNeo      
ALE-3.01 p416-4xUASaro-Leumin-KanNeo      
ALE-3.02 p416-4xUASaro-Leumin-KanNeo      
ALE-3.03 p416-4xUASaro-Leumin-KanNeo      
ALE-3.04 p416-4xUASaro-Leumin-KanNeo      
ALE-3.05 p416-4xUASaro-Leumin-KanNeo      
ALE-3.06 p416-4xUASaro-Leumin-KanNeo      
ALE-4.01 p416-4xUASaro-Leumin-KanNeo      
ALE-4.02 p416-4xUASaro-Leumin-KanNeo      
ALE-4.03 p416-4xUASaro-Leumin-KanNeo      
ALE-4.04 p416-4xUASaro-Leumin-KanNeo      
ALE-4.05 p416-4xUASaro-Leumin-KanNeo      
ALE-4.06 p416-4xUASaro-Leumin-KanNeo      
ALE-4.07 p416-4xUASaro-Leumin-KanNeo      
ALE-4.08 p416-4xUASaro-Leumin-KanNeo      
ALE-4.09 p416-4xUASaro-Leumin-KanNeo      
ALE-4.10 p416-4xUASaro-Leumin-KanNeo      
ALE-4.11 p416-4xUASaro-Leumin-KanNeo      
ALE-4.12 p416-4xUASaro-Leumin-KanNeo      
ALE-4.13 p416-4xUASaro-Leumin-KanNeo      
ALE-4.14 p416-4xUASaro-Leumin-KanNeo      
ALE-4.15 p416-4xUASaro-Leumin-KanNeo      
ALE-4.16 p416-4xUASaro-Leumin-KanNeo      
ALE-4.17 p416-4xUASaro-Leumin-KanNeo      
ALE-4.18 p416-4xUASaro-Leumin-KanNeo      
ALE-4.19 p416-4xUASaro-Leumin-KanNeo      
ALE-4.20 p416-4xUASaro-Leumin-KanNeo      
ALE-4.21 p416-4xUASaro-Leumin-KanNeo      
ALE-5.01 p416-4xUASaro-Leumin-KanNeo      
ALE-5.02 p416-4xUASaro-Leumin-KanNeo      
ALE-5.03 p416-4xUASaro-Leumin-KanNeo      
ALE-5.04 p416-4xUASaro-Leumin-KanNeo      
ALE-5.05 p416-4xUASaro-Leumin-KanNeo      
ALE-5.06 p416-4xUASaro-Leumin-KanNeo      
ALE-5.07 p416-4xUASaro-Leumin-KanNeo      
ALE-5.08 p416-4xUASaro-Leumin-KanNeo      
ALE-5.09 p416-4xUASaro-Leumin-KanNeo      
ALE-5.10 p416-4xUASaro-Leumin-KanNeo      
ALE-1.02     5-FoA 
Table 4.2: continued next page. 
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ALE-2.08     5-FoA 
ALE-5.01     5-FoA 
Pop-1.02.1 p416-4xUASaro-Leumin-KanNeo    EMS 1x99% Kill 
Pop-1.02.2 p416-4xUASaro-Leumin-KanNeo    EMS 2x99% Kill 
Pop-1.02.0 p416-4xUASaro-Leumin-KanNeo    Control 
Pop-2.08.1 p416-4xUASaro-Leumin-KanNeo    EMS 1x99% Kill 
Pop-2.08.2 p416-4xUASaro-Leumin-KanNeo    EMS 2x99% Kill 
Pop-2.08.0 p416-4xUASaro-Leumin-KanNeo    Control 
Pop-5.01.1 p416-4xUASaro-Leumin-KanNeo    EMS 1x99% Kill 
Pop-5.01.2 p416-4xUASaro-Leumin-KanNeo    EMS 2x99% Kill 
Pop-5.01.0 p416-4xUASaro-Leumin-KanNeo    Control 
ALE-1.02.1.01 p416-4xUASaro-Leumin-KanNeo      
ALE-1.02.1.02 p416-4xUASaro-Leumin-KanNeo      
ALE-1.02.1.03 p416-4xUASaro-Leumin-KanNeo      
ALE-1.02.1.04 p416-4xUASaro-Leumin-KanNeo      
ALE-1.02.1.05 p416-4xUASaro-Leumin-KanNeo      
ALE-1.02.2.01 p416-4xUASaro-Leumin-KanNeo      
ALE-1.02.2.02 p416-4xUASaro-Leumin-KanNeo      
ALE-1.02.2.03 p416-4xUASaro-Leumin-KanNeo      
ALE-1.02.2.04 p416-4xUASaro-Leumin-KanNeo      
ALE-1.02.2.05 p416-4xUASaro-Leumin-KanNeo      
ALE-2.08.0.01 p416-4xUASaro-Leumin-KanNeo      
ALE-2.08.0.02 p416-4xUASaro-Leumin-KanNeo      
ALE-2.08.0.03 p416-4xUASaro-Leumin-KanNeo      
ALE-2.08.0.04 p416-4xUASaro-Leumin-KanNeo      
ALE-2.08.0.05 p416-4xUASaro-Leumin-KanNeo      
ALE-5.01.1.01 p416-4xUASaro-Leumin-KanNeo      
ALE-5.01.1.02 p416-4xUASaro-Leumin-KanNeo      
ALE-5.01.1.03 p416-4xUASaro-Leumin-KanNeo      
ALE-5.01.1.04 p416-4xUASaro-Leumin-KanNeo      
ALE-5.01.2.01 p416-4xUASaro-Leumin-KanNeo      
ALE-5.01.2.02 p416-4xUASaro-Leumin-KanNeo      
ALE-5.01.2.03 p416-4xUASaro-Leumin-KanNeo      
ALE-5.01.2.04 p416-4xUASaro-Leumin-KanNeo      
ALE-1.02.1.04     5-FoA 
ALE-1.02.2.01     5-FoA 
ALE-5.01.1.02     5-FoA 
ALE-5.01.2.01     5-FoA 
ALE-1.02   
XII::5xUASaro-CORE1-
yECitrine Integration 
ALE-2.08   
XII::5xUASaro-CORE1-
yECitrine Integration 
ALE-5.01   
XII::5xUASaro-CORE1-
yECitrine Integration 
Table 4.2: continued next page. 
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ALE-1.02.1.04   
XII::5xUASaro-CORE1-
yECitrine Integration 
ALE-1.02.2.01   
XII::5xUASaro-CORE1-
yECitrine Integration 
ALE-5.01.1.02   
XII::5xUASaro-CORE1-
yECitrine Integration 








 Mat a; his Δ1; leu2Δ0; 
met15Δ0; ura3Δ0; 
aro3Δ; aro4Δ::PGPD-









 Mat a; his Δ1; leu2Δ0; 
met15Δ0; ura3Δ0; 
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 Mat a; his Δ1; leu2Δ0; 
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 Mat a; his Δ1; leu2Δ0; 
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 Mat a; his Δ1; leu2Δ0; 
met15Δ0; ura3Δ0; 
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 Mat a; his Δ1; leu2Δ0; 
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 Mat a; his Δ1; leu2Δ0; 
met15Δ0; ura3Δ0; 
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 Mat a; his Δ1; leu2Δ0; 
met15Δ0; ura3Δ0; 
aro3Δ; aro4Δ::PGPD-








Table 4.2: Yeast strains used in this chapter.  
A table of yeast used in this chapter, their lineage, plasmids harbored and known 





Chapter 5:  Materials and Methods 
 
5.1 COMMON MATERIALS AND METHODS 
5.1.1 Strains and media 
Saccharomyces cerevisiae strain BY4741 (Mat a; his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0) was used as the primary host strain for this work (obtained from EUROSCARF).  
Yeast strains were routinely propagated at 30°C in Yeast Extract Peptone Dextrose 
(YPD) medium, yeast synthetic complete (YSC) medium, or yeast synthetic minimal 
(YSM) medium.  YPD medium is composed of 10 g/L yeast extract, 20 g/L peptone, and 
20 g/L glucose.  YSC medium is composed of 6.7 g/L yeast nitrogen base, 20 g/L 
glucose, and either CSM-Ura, CSM-His, CSM-Leu, CSM-Trp or combination thereof 
(MP Biomedicals, Solon, OH), depending on the required auxotrophic selection.  YSM 
medium is composed of 6.7 g/L yeast nitrogen base, 20 g/L glucose, 20 mg/L methionine, 
and 10 mg/L adenine.  Escherichia coli strain DH10β was used for all cloning and 
plasmid propagation. DH10β was grown at 37 °C in Luria-Bertani (LB) broth 
supplemented with 50 μg/mL of ampicillin.  All strains were cultivated with 225 RPM 
orbital shaking.  Yeast and bacterial strains were stored at -80°C in 15% glycerol 
5.1.2 Plasmid construction  
Standard cloning and bacterial transformations were performed according to 
Sambrook and Russell [168].  Genomic DNA from S. cerevisiae and E. coli were 
obtained using Wizard Genomic DNA Extraction Kit from Promega. PCR reactions used 
Phusion High-Fidelity DNA Polymerase from New England Biolabs (Ipswich, MA) and 
followed supplier instructions; primers were purchased from Integrated DNA 
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Technologies (Coralville, Iowa).  Antarctic phosphatase and all restriction enzymes were 
purchased from New England Biolabs (Ipswich, MA).  Fermentas T4 DNA ligase and all 
other enzymes and chemicals were purchased through Thermo Fisher Scientific 
(Waltham, MA).  Vectors were isolated using the Zyppy Plasmid Miniprep kit from 
Zymo Research Corp. (Irvine, CA) and DNA purification was performed with a Qiaquick 
PCR Cleanup kit (Qiagen, Valencia, CA).  Some cloning procedures required gel 
extraction, which was accomplished with the Fermentas GeneJET Gel Extraction Kit 
from Thermo Fisher Scientific (Waltham, MA).  All plasmids and genes were sequenced 
confirmed to ensure correct identify of the insert prior to yeast transformations 
 
 
5.2 MATERIALS AND METHODS FOR CHAPTER 2 
 
5.2.1 Plasmid construction  
With the exception of integration vectors, all plasmids were constructed using 
standard yeast plasmids with either the TEF2 or GPD (TDH3) promoter from {Mumberg, 
1995 #68} (Table 2.1, at the end of the chapter).  The following genes: AroZ and AroY 
from Klebsiella pneumoniae, CatA from Acinetobacter baylyi, QutC from Aspergillus 
niger, Pa_5_5120, Pa_0_880, and Pa_4_4540 from Podospora anserina, ECL_01944 
from Enterobacter cloacae, and HQD2 from Candida albicans were codon-optimized for 
expression in S. cerevisiae and synthesized by Blue Heron Biotechnology (Bothell, WA).  
These genes were either gel extracted or cloned via PCR (see Table 2.1 for primers) and 
inserted into the desired plasmid mulitcloning site using the XbaI or SpeI site at the 5’ 
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end of the gene and the ClaI, EcoRI or SalI site at the 3’ end of the gene.  The FDC1, 
PAD1 and ARO4 genes from S. cerevisiae and DEHA2F15906g, DEHA2G00682g and 
DEHA2C14806g from Debaryomyces hansenii were cloned via PCR from extracted 
gDNA (obtained using the Wizard Genomic DNA Extraction Kit from Promega, 
Madison, WI).  The wildtype K. pneumoniae AroZ and AroY genes and A. baylyi CatA 
gene were cloned from E. coli expression plasmids provided by Draths Corporation.   
When it was desired to express two genes on a single plasmid, each was first 
cloned into a separate plasmid as described above, and then the expression cassette 
containing one of the genes, including the surrounding promoter and terminator, was 
cloned into a single restriction site on the other plasmid. 
The  feedback-resistant ARO4 mutant, aro4k229l, was created by cloning the 
wildtype gene into a vector to create p416-TEF-scARO4 and then using the QuikChange 
Site-Directed Mutagenesis Kit from Agilent Technologies (Santa Clara, CA) to make the 
desired mutations as described by Luttik and coworkers [100], resulting in plasmid p416-
TEF-scaro4k229l (Table 2.1, at the end of the chapter ). 
5.2.2 Strain construction 
All S. cerevisiae strains were constructed from BY4741 (Mat a; his3Δ1; leu2Δ0; 
met15Δ0; ura3Δ0) as the initial strain (Table 2, at the end of the chapter).  Plasmids were 
transformed using the EZ Yeast Transformation II Kit from Zymo Research Corp. 
(Irvine, CA).  Gene knockouts were generated using the “delete and repeat” method 
[123].  Gene disruption cassettes containing the KanMX selectable marker flanked by 
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loxP sites (obtained by PCR of the pUG6 plasmid [123]) were produced with 40 
basepairs of homology on either side of each target integration site.  Following yeast 
transformations, colonies were selected on 200mg/L G418 and PCR confirmed (see 
Table 2.1 for primers, located at the end of the chapter).  
Multiple gene knockouts were achieved using an interspersed step with Cre 
recombinase to excise the selection marker between the loxP sites in the disruption 
cassette.  Cre recombinase was expressed using the inducible GAL1 promoter on plasmid 
pSH47 [123].  Once marker removal was achieved, the strain was grown in YPD plus 
1g/L 5-flouroorotic acid to encourage loss of the URA3 containing pSH47 plasmid [169].  
The mutant aro4k229l was integrated into the ARO4 locus by cloning the 
expression cassette, including promoter and terminator, from p416-GPD- scaro4k229l and 
inserting it into the pUG6 plasmid in order to create an integration cassette with the 
KanMX selectable marker.  The insertion cassette was then cloned and transformed as 
described above for the gene disruption cassettes. 
To integrate ECL_01944opt, the expression cassette from p425-GPD- 
ECL_01944opt, including the promoter and terminator, was cloned into vector pITy3 
[101].  The resulting vector, pITy-GPD- ECL_01944opt, was digested with the ScaI 
restriction enzyme to create a linear integration cassette for multiple integrations into the 
Ty2 δ sites [101].  Clones with multiple integrations were preferentially selected on 
higher concentration G418 plates (500 mg/L). 
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5.2.3 Enzyme activity assays 
 
Dehydroshikimate (DHS) dehydratase and catechol 1,2-dioxygenase activities 
were assayed using total cell protein extract, which was obtained using the Pierce Y-PER 
Yeast Protein Extraction Reagent and EDTA-free Halt Protease Inhibitor from Thermo 
Fisher Scientific (Waltham, MA).  The protein extraction was performed according to Y-
PER reagent instructions.  Protein concentration was determined using the BCA method 
with a Pierce BCA kit obtained from Thermo Fisher Scientific (Waltham, MA).  
Spectrophotometric assays for enzyme activity were then performed [170, 171].  For the 
DHS dehydratase, 300μg of protein was added to a cuvette containing excess Y-PER 
reagent and DHS such that the final concentration of DHS was 0.1-0.75 mM in a total 
volume of 1 mL.  A reading of the absorbance at 290 nm was taken every 20 seconds for 
three minutes.  For the catechol 1,2-dioxygenase, 300µL of protein (at approximately 
1000 ug/mL) was added to a cuvette containing 100mM potassium phosphate buffer 
(pH=7.5) and catechol such that the final concentration of catechol was 0.1-0.4mM in a 
total volume of 1 mL.  A reading of the absorbance at 288nm was taken every 2 seconds 
for approximately 90 seconds total.  For both DHS dehydratase and catechol 1,2-
dioxygenase, product formation was quantified using standard curves of the expected 
reaction product (PCA or cis,cis-muconic acid, respectively) in the presence of control 
protein extract (from cultures not producing the heterologous enzymes) as well as with 
varying amount of reactant (DHS or catechol, respectively) in order to take into account 
all possible contributions to absorbance.  An Ultrospec 2100 pro UV/Visible 
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Spectrophotometer from Biochrom (Cambridge, UK) was used in the assays.  DHS was 
obtained from Sigma-Aldrich (St. Louis, MO).  Catechol, PCA, and cis,cis-muconic acid 
were obtained from Thermo Fisher Scientific (Waltham, MA). 
5.2.4 Strain characterization 
High pressure liquid chromatography (HPLC) was used to measure the production 
of muconic acid and pathway intermediates in S. cerevisiae cultures.  Strains were pre-
cultured in 5 mL aliquots for two days and used to inoculate 30 mL flask cultures at 
OD600=0.25.  After a designated time (usually 48 hours for initial characterizations), the 
OD600 was measured and a 1 mL sample was taken and pelleted for 5 min. at 3,000x g.  
The supernatant was filtered using a 0.2 micron syringe filter from Corning Incorporated 
(Corning, NY).  Samples were then separated using a HPLC Ultimate 3000 from Dionex 
(Sunnyvale, CA) and a Zorbax SB-Aq column from Agilent Technologies (Santa Clara, 
CA).  A 2.0 μL injection volume was used in a mobile phase composed of an 84:16 ratio 
of 25mM potassium phosphate buffer (pH=2.0) to acetonitrile with a flow rate of 1.0 
mL/min.  The column temperature was maintained at 30ºC and the UV-Vis absorption 
was measured at 280nm.  Standards, including DHS, PCA, catechol, and cis,cis-muconic 
acid, were purchased from Sigma-Aldrich (St. Louis, MO).  Cis, trans-muconic acid was 
generously provided by Draths Corporation. 
 Glucose utilization in the 30 mL flask cultures was measured using a YSI 
7100 MBS from YSI Life Sciences (Yellow Springs, Ohio) according to manufacturer 
instructions.  Culture supernatant was diluted 1:10 in DI water prior to measurement. 
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5.2.5 RT-PCR Analysis 
The relative abundance of heterologous mRNA was determined using quantitative 
RT-PCR.  RNA was extracted from mid-log phase cells using the Ambion Yeast Ribo-
Pure Kit (Life Technologies, Carlsbad, CA) and cDNA was prepared using the Applied 
Biosystems High Capacity Reverse Transcription Kit (Life Technologies, Carlsbad, CA).  
Primers were designed using the Primer Quest utility from Integrated DNA Technologies 
(Coralville, Iowa), including primers for ECL_01944opt 
(TGCATGGTTTCTCATTGTGACGGC and CAACATACAAACACTGGCCACGCT) 
and for ALG9 (ATCGTGAAATTGCAGGCAGCTTGG  and 
CATGGCAACGGCAGAAGGCAATAA), which was used as the housekeeping gene.  
Quantitative PCR was performed on a ViiA7 Real Time PCR System (Life Technologies, 
Carlsbad, CA) using Fast Start SYBR Green Master Mix (Roche, Penzberg, Germany), 
following the manufacturer’s instructions with an annealing temperature of 58°C.  
5.2.6 Flux balance analysis calculations 
Flux balance analysis calculations were performed on a Dell PC using MATLAB 
(Mathworks, Natick, MA) and the Cobra Toolbox add-in [18, 172].  The iMM904 
genomic scale model was used [109].  The reactions representing the heterologous 
enzymatic activity of DHS dehydratase, PCA decarboxylase, and catechol 1,2-
dioxygenase were added to the model as shown in Table 2.3.  Maximum theoretical 
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yields were calculated by setting the muconic acid production reaction ‘EX_MUA’ as the 
objective function and solving the system of linear equations.   
5.3 MATERIALS AND METHODS FOR CHAPTER 3 
5.3.1 Plasmid construction 
UASaro elements were amplified from BY4741 gDNA (Wizard Kit, Zymo 
Research), purified, restriction digested and ligated generate p416-1x UASaro -LeuMin-
yECitrine. Additional UASaro elements were sequentially added through restriction 
cloning.  The 4x UASaro cassette and p416-CYC-yECitrine were PCR amplified, gel 
extracted and used to Gibson assemble p416-5x UASaro -CYC1-yECitrine [173]. The 
5xUASaro cassette was then digested out with BamHI/PmeI and ligated into p416-HXT7-
yECitrine, p416-CORE1-yECitrine, p416-LeuMin-yECitrine.  
Yeast homologous recombination was used to assemble p415-TEF-aro80, by 
transforming the linearized fragments into BY4741 and selecting on CSM-LEU plates 
followed by purifying the resulting plasmids [174].  The S551I point mutation was 
generated using the Quickchange II kit (Strategene), while the T675S point mutation and 
p416-CORE1-yECitrine  vector were constructed using inverse PCR followed by blunt 
end ligation.  A table of resulting strains from plasmid transformations is provided in 
Table 3.2. 
5.3.2 ARO80 Library Preparation 
ARO80 gene was amplified from the p415-TEF-ARO80 plasmid DNA (primers 
listed in Table 3.1) using the Genemorph II kit (Strategene, La Jolla, Ca) according to 
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manufacturer’s recommendations. This PCR product was confirmed by gel 
electrophoresis and digested overnight with SpeI-HF and XhoI. The p415-TEF vector 
was digested, phosphatased and insert ligated overnight and transformed into E. coli and 
resulting transformants spread over 15cm plates, reaching a library size of 4x104.  E. coli 
colonies were then scrapped from the plates, votexed, glycerol stocked and miniprepped 
(Thermo).  This library was then transformed into the aro80Δ- p416-4x UASaro-LeuMin-
yECitrine strain using the high-efficiency yeast transformation protocol [175] and 
resuspended in a 300ml liquid culture. A fraction was plated in order to estimate the 
effective library size present of 5x105.  
 
5.3.3 Flow Cytometry and FACS 
The yeast cultures were inoculated in triplicate from glycerol stock in CSM-URA 
or CSM-URA-LEU and grown until stationary phase. All cultures were then inoculated at 
an OD600 of 0.01 in fresh media and grown to mid-log phase in 30℃ orbital shaker for 
14-16 hours. Induction was accomplished by subculturing from stationary phase in CSM 
into media containing 500mg/L or 1g/L L-Tryptophan or 20g/L galactose.  Fluorescence 
was analyzed on the Fortessa Flowcytometer (BD Biosciences) using the yECitrine 
fluorophore. 10,000 events were gathered at a flow rate of 1,000 events per second and 
analyzed using the FlowJo software suite. Data for the Digital-to-Analog converter 
described in Figure 3.5 were grown in a 96-deep well block, 1ml culture volume and the 
fluorescence analyzed using the Accuri Flowcytometer (BD Biosciences).  An average of 
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the fluorescence and standard deviation within biological replicates is provided.  All 
experiments within a single graph were conducted on the same day at the same time. 
The top 1% fluorescing cells from the aro80-library were sorted using the BD 
FACS Aria Cell sorter. Recovered cells were grown for 24 hours at 30℃in 2ml of CSM-
URA-LEU media and plated to solid media. Individual colonies were randomly selected, 
inoculated to 2ml of CSM-URA-LEU and fluorescence compared to the control strains. 
5.3.4 qPCR Analysis 
S. cerevisiae BY4741 strains expressing amplifier circuit and GPD-YFP plasmids were 
inoculated from glycerol stock into CSM-URA-LEU and CSM-URA respectively. These 
were cultured for 48 hours and then inoculated into fresh media at OD600 of 0.01 in 2ml 
of fresh media and cultured for 15 hours with shaking. Total RNA was extracted from 1 
OD unit of cells (Quick-RNA Miniprep, Zymo Research). 500ng of RNA was reverse 
transcribed (High Capacity cDNA Reverse Transcription Kit, Applied Biosystems) and 
quantified in triplicate (SYBR Green PCR Master Mix, Life Technologies) after RNA 
extraction. Transcript levels were quantified using primers previously designed to target 
yECitrine (TTCTGTCTCCGGTGAAGGTGAA and 
TAAGGTTGGCCATGGAACTGGCAA)[62] and that of the housekeeping gene ALG9 
(ATCGTGAAATTGCAGGCAGCTTGG and CATGGCAACGGCAGAAGGCAATAA) 
[176]. Reactions were performed on the Viia 7 Real Time PCR Instrument (Life 
Technologies) and data analyzed using Viia 7 Software. 
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5.4 MATERIALS AND METHODS FOR CHAPTER 4 
5.4.1 Plasmid Construction 
Gibson Assembly [173] was used to construct the PugM vector with 
ECL_01944opt under control of the UASCLB–UASCIT–UASTEF-GPD hybrid 
promoter [62] followed by the Tprm9 high capacity terminator [131] with parts amplified 
with primers listed in Table 1.  The PugM and p425-TEF-pa5_5120opt/GPD-caHQD2opt 
vectors were used to amplify parts to construct p426-TEF-pa5_5120opt-Tcyc-GPD-
ECL_01944opt-Tprm9 through Gibson Assembly. MoClo assembly was used to 
construct the PAD1 integration vector. A “Type 3” entry vector was built for scPAD1 
using BsmbI golden gate assembly. The PAD1 integration vector, scPAD1-IV, was 
assembled from “part vectors” listed in Table 4.1 using BsaI golden gate assembly [177]. 
5.4.2 Growth Rate Analysis  
 
Strains of interest were precultured for 3 days in the appropriate selective 
medium, and 1 μL of this precultured was used as an inoculum for a 250 μL culture in the 
same selective medium. Growth rate measurements were then obtained using a Bioscreen 
C (Growth Curves USA). 
5.4.3 Flow Cytometry 
 
For the initial biosensor assay, yeast cultures were inoculated in triplicate from 
glycerol stock in CSM-URA for two days at stationary phase. All cultures were then 
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inoculated at an OD600 of 0.01 in fresh media and grown to mid-log phase in 30℃ orbital 
shaker for 14-16 hours. Induction was accomplished by subculturing from stationary 
phase in CSM into media containing 500mg/L L-Tryptophan, 500mg/L L-Phenylalanine 
or 100mg/L Tyrosine. Fluorescence was analyzed on the Fortessa Flowcytometer (BD 
Biosciences) using the yECitrine fluorophore. 10,000 events were gathered at a flow rate 
of 1,000 events per second and analyzed using the FlowJo software suite. 
For the integrated fluorescent biosensor assay, yeast cultures were inoculated in 
triplicate from glycerol stock in CSM-HIS in a 96-deep well block, 1ml culture volume 
and the fluorescence analyzed using the Accuri Flowcytometer (BD Biosciences).  An 
average of the fluorescence and standard deviation within biological replicates is 
provided.  All experiments within a single graph were conducted on the same day at the 
same time. 
5.4.4 EMS Mutagenesis 
 
The EMS mutagenesis procedures were performed following the protocol 
described by Winston [163]. An overnight culture was cultivated to OD600 of 1.0. Cells 
were then harvested, washed and suspended with 0.1M sodium phosphate buffer (pH 7). 
30ul of EMS was added and incubated along with an unmutagenized control for 1 h at 
30℃, with agitation. The cells were then washed twice with 5% sodium thiosulfate to 
eliminate residual EMS and the cells were allowed to recover in CSM-URA. This 
 120 
procedure was repeated on a portion of mutagenized cells. Kill fraction was calculated by 
plating a fraction from mutagenized and control populations.  
5.4.5 Subculturing Procedure 
 
Following EMS mutagenesis the recovered cells were sequentially subcultured in 
30ml of CSM-URA media. After reaching stationary phase, 100ul of cells were 
transferred to 30ml of fresh selective media with increasing concentrations of G418 and 
analog. During this first round of selection the populations were subcultured six times 
and cultured for over 750 hours after which the unmutagenized control populations were 
unable to grow in the selective media conditions while the mutagenized populations 
continued to grow in 1000 mg/L G418 and 2mM 4-FP.  
During the second round of selection, following recovery from EMS, the cultures 
were inoculated into 1000 mg/L G418 and 1mM 4-FP. Over the course of selection, the 
4FP selective concentration was increased to 7.5mM which resulted in an observed 
growth rate difference between the populations.  Following selection, colonies were 
plated and isolated. Colonies were selected and the strain was grown in YPD plus 1 g/L 
5-flouroorotic acid to encourage loss of the URA3 containing pSH47 plasmid [169]. 
5.4.6 Tyrosine Quantification 
Tyrosine quantification was confirmed using four different protocols. The first 
protocol used to quantify the data reported in Figure 4.4 used cultures directly selected 
from CSM-URA plates following selection. OD600 measurements were taken and 100ul 
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of supernatant were isolated and assayed using nitrosonapthol chemical derivation using 
nitrosonapthol derivatization which had been previously developed  [164]  and analyzed 
using the BioTek Cytation 3 plate reader. Tyrosine concentration was calculated based on 
standards and production. 
The second protocol used to quantify the data reported in Figure 4.6 used cultures 
directly selected from YPD plates into 4ml of YPD liquid media. OD600 measurements 
were taken and cells were resuspended to reach 0.5 OD600 in 4ml of fresh 2% glucose 
CSM. After 48 hour of culturing, 300ul of supernatant extracted and quantified with the 
derivatization protocol listed above. The third protocol used to quantify the data reported 
in Figure 4.7 used cultures directly selected glycerol storage into 4ml of 4% glucose 
CSM. OD600 measurements were taken and cells were resuspended to reach 0.1 OD600 in 
30ml of fresh 4% glucose CSM in 250ml shake flasks. After 70 hour of culturing, 300ul 
of supernatant extracted and quantified with the derivatization protocol listed above.  
 
The fourth protocol was used to quantify the data reported in Figure 4.8.  96-deep 
well blocks were inoculated from glycerol stock and grown to stationary phase. OD600 
was measured with BioTek Cytation 3 plate reader and the block spun down and cells 
washed with water. The cells were then cultured overnight in minimal media without 
YNB. After 16 hours of incubation, the cells were pelleted and the supernatant extracted. 
Tyrosine in the supernatant was quantified using nitrosonapthol derivatization described 
above. Tyrosine concentration was calculated based on standards and production 




High performance liquid chromatography (HPLC) was used to measure the 
production of muconic acid and pathway intermediates in S. cerevisiae cultures. Strains 
were pre-cultured in 4mL aliquots until they reached stationary phase and used to 
inoculate 30 mL flask cultures at OD600 = 0.1. At designated times (72, 120 and 168 h), 
the OD600 was measured and a 1.5 mL sample was taken and pelleted for 5 min. at 3000 x 
g. The supernatant was filtered using a nylon 0.2 mm syringe filter from Corning 
Incorporated.  
Samples were then separated using a HPLC Ultimate 3000 from Dionex with 
dilution as required.  Composite pathway products were quantified using the Zorbax SB-
Aq column from Agilent Technologies. A 10.0 uL injection volume was used in a mobile 
phase composed of an 84:16 ratio of ddH2O with 0.1% Trifluoroacetic Acid to 
acetonitrile with 0.1%  TFA with a flow rate of 1.0 mL/min. Column temperature was 
maintained at 30℃ and UV–Vis absorption was measured at 280 nm. Peaks were 
compared to a standard curve including PCA, catechol, and cis,cis-muconic acid, 
purchased from Sigma-Aldrich. Cis, trans-muconic acid had been previously provided by 
Draths Corporation. Reported value represents the highest titer reached during the three 
timepoints assayed.  
Glucose quantification was accomplished using the Aminex HPX-87p 
Carbohydrate Column from Bio-Rad Laboratories  with RI detection performed by 
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Refractomax 520 modular unit. The mobile phase was 100% ddH2O, with a flow rate of 
0.6mL/min. The column temperature was maintained at 85℃.    
5.4.8 Bioreactor Fermentations 
 
Bioreactor fermentations were run using a Bioflo 115 (New Brunswick) using 
CSM-LUHW with 4% glucose as a fed-batch process with up to three media spikes 
throughout the run. All fermentations were inoculated to an initial OD600 = 0.2 in 1.7L of 
media. Dissolved oxygen was maintained through cascaded agitation with a constant air 
input flow rate of 0.5 SLPM. The pH was maintained at 5.0 with 1M NaOH and 
temperature was maintained at 30℃. Throughout the run, 21 mL of samples were 
removed from the reactor and fermentations lasted up to 12 days.  
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Chapter 6: Conclusions and Major Findings 
6.1 MAJOR FINDINGS 
The experiments described here represent a synthesis of metabolic engineering, 
synthetic biology and adaptive laboratory evolution. We begin with the initial work of 
developing a composite pathway capable of producing muconic acid in yeast followed up 
by rational metabolic engineering to improve titers. To further strain development, we 
engineer a biosensor capable of detecting the downstream products of the shikimate 
pathway, aromatic amino acids. We demonstrate the utility of this biosensor through the 
development of a mutant ARO80p as a proof of concept.  Finally, we use this biosensor 
to develop a strain of yeast capable of increased muconic acid production titers which 
represents the highest titers produced of this molecule in a yeast host. 
For our first aim, we screened seventeen potential enzymes to build a composite 
pathway capable of producing muconic acid in S. cerevisiae utilizing enzymatic activity 
assays to confirm enzyme function. This pathway consisted of: caHQD2opt, pa5_5120opt 
and kpAroYopt. With a functional muconic acid pathway drawing off of flux from the 
shikimate pathway built, we removed the feedback inhibition previously shown to exist 
within the aromatic amino acid biosynthetic pathway by knocking-out ARO3/ARO4 and 
integrating the feedback resistant mutant of aro4k229l. However, this composite pathway 
needed balancing as we were producing a high concentration of PCA relative to our 
muconic acid production. Thus, we optimized our pathway by employing a higher 
performing PCA decarboxylase, the AroY gene ECL_01944opt, and transferred the 
pathway to a combination of high copy plasmids and genomic integration. Next, we used 
flux balance analysis to predict metabolic changes which could re-route flux into our 
composite pathway and improve muconic acid yields and titers. The solution predicted 
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for increasing flux into the starting point of the shikimate pathway, erythrose-4-phosphate 
and phosphoenolpyruvate was to overexpress the transketolase gene TKL1 and 
subsequently knockout the glucose-6-phosphate dehydrogenase gene, ZWF1, to force 
entry into the pentose phosphate pathway to occur via transketolase. With final media 
optimization, we were able to report a titer of 141 mg/L muconic acid, 24 times the value 
of the initial strain.  
The second goal was to develop an aromatic amino acid biosensor and utilize this 
sensor for the engineering of its activator, the transcription factor ARO80p. This 
application would function as a proof of concept for further applications of this biosensor 
for engineering S. cerevisiae at the protein or genome level for higher production of 
aromatic amino acids and muconic acid. We used this biosensor to accomplish the 
engineering of both cis DNA elements and the trans-acting factor responsible for their 
activation.  The first step in this process was to develop a hybrid promoter based on the 
ARO9 promoter previously demonstrated to be sensitive to exogenous concentrations of 
aromatic amino acids. We cloned this UASaro element 5’ of the LeuMin minimal 
promoter element and demonstrated that it could be induced as well as the wild-type 
ARO9 promoter.  
Having demonstrated that we could employ a hybrid approach to developing an 
ARO9 based biosensor, we expanded hybrid promoter to include 4x-UASaro elements 
and demonstrated that in conjunction with ARO80wt overexpression, that we could 
observe a stronger signal through the hybrid promoter than the native ARO9 promoter 
while maintaining a 2.5 fold induciblity with exogenous tryptophan.  Having developed a 
cis-architecture capable of stronger expression, we turned our attention to increasing the 
strength of its trans-acting factor ARO80p. We then screened a protein library of ARO80 
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and isolated the ARO80mut containing two point mutations I551S and S675T. When 
paired with the 4xUASaro-LeuMin promoter, it resulted in constitutive expression 5-fold 
of the ARO80wt, while still maintaining its inducibility.  
We then employed this ARO80mut to produce two synthetic genetic circuits. The 
first circuit implemented was that of an “amplifier” to generate ultra-strong promoters. 
The ARO80mut was expressed under control of the strong TEF promoter, while 4 or 
5xUASaro elements were placed 5’ of full length promoters HXT7 and CYC1 as well as 
LeuMin and CORE1 minimal promoters. At best, this resulted in 15-fold amplification 
compared to the core promoters and up to a 2-fold increase in protein expression 
compared to GPD, one of the strongest available constitutive promoters.  
We then implemented a circuit capable of staged, multi-output response, 
previously termed a “Digital-to-Analog converter”. We placed the aro80mut under the 
GAL1 promoter while using it to drive expression from three hybrid promoters 
constructs. By controlling the concentration of tryptophan and use of glucose or 
galactose, we were able to produce staged expression outputs. We then were able to 
remove one of the stages by knocking out the endogenous ARO80wt, limiting the 
tryptophan induction without growth in galactose.  The application of the biosensor to 
engineer the transcription factor responsible for its activation provides a useful proof-of-
concept for further engineering efforts.  
The third goal was to utilize this biosensor to develop improved yeast strains for 
muconic acid production. To investigate potential mutations beneficial for muconic acid 
production, we employed an adaptive laboratory evolution experiment (ALE) with the 
aromatic amino acid production functioning as a surrogate for muconic acid, as aromatic 
amino acids are derived from the same pathway. We first demonstrated that this ARO9 
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based biosensor was capable of detecting intracellular concentrations of aromatic amino 
acids as well as extracellular by expressing it in our previously engineered strain with 
aro3Δ; aro4Δ::PGPD-aro4k229l; zwf1Δ (ENG) and comparing it to expression in BY4741. 
We then demonstrated that the biosensor could detect further improvements by inducing 
the biosensor in BY4741 and ENG with exogenous tryptophan, tyrosine and 
phenylalanine. Next, we turned to developing a growth based selection scheme for use in 
ALE. We built an aromatic amino acid inducible G418 antibiotic resistance vector using 
the 4xUASaro-LeuMin promoter to drive expression of the weak KanNeo gene.  
We then mutagenized the ENG strain expressing the KanNeo biosensor with EMS 
and then performed serial sub-culture to enrich the population of cells for improved 
growth under increasing selective conditions of G418 and the anti-metabolites 4-
Fluorophenylalanine to provide additional selection pressures for producing aromatic 
amino acids, This resulted in three ALE isolated strains which we showed, using tyrosine 
quantification and a fluorescent biosensor, to have improved aromatic amino acid 
production. These were then used for a second round of ALE resulting in four strains 
with improved aromatic amino acid production. The muconic acid composite pathway 
was transformed into these strains and they showed a three-fold improvement in pathway 
output relative to the ENG strain. Next we rerouted flux into our composite pathway 
through a truncated ARO1 protein and overexpression of the native yeast PCA 
decarboxylase PAD1. This resulted in a strain of yeast capable of 550mg/L muconic acid 
production in flask. We then scaled this up to 3 L bioreactor fermentations and employed 
dissolved oxygen control to result in 1.94 g/L production, the highest reported titer of 
muconic acid produced in S. cerevisiae as well as the highest reported titer of any 
shikimate derivative.   
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In summary, this chapter represents the first demonstration of muconic acid 
production in S. cerevisiae and the application of rational and evolutionary techniques to 
bring it from a proof of concept (mg/L) to industrially relevant levels of production (g/L). 
Contributing to this work was the development and application of a biosensor capable of 
detecting intracellular and extracellular aromatic amino acids and its use in an adaptive 
laboratory evolution scheme. This biosensor was then utilized in a cis-trans combined 
engineering approach to develop an ultra-strong expression system for use in S. 
cerevisiae resulting in a promoter twice as strong as GPD, one of the strongest 
endogenous promoters in yeast.  
 
6.2 PROPOSALS FOR FUTURE WORK 
The studies described here demonstrate the combination of metabolic engineering 
with evolutionary studies. This could be further expanded by using this aromatic amino 
acid biosensor in protein engineering applications to engineer improved TKL1, ARO1 
other regulatory enzymes such as GCN4 which are involved in aromatic amino acid 
metabolism. The availability of biosensors for use in S. cerevisiae is expanding, and the 
ALE scheme demonstrated could be easily retuned for improved flux through other 
metabolites. 
The ARO80mut trans-acting factor facilitating a strong output from small and 
modular promoters it could be used to enable the expression of other complex genetic 
circuits. With the small DNA footprint of the UASaro element, it could be used to 
express heterologous promoters from bacterial species to facilitate the importing of 
bacterial operons into eukaryotic hosts. Finally, other researchers have shown that 
ARO80 expression can be modulated by temperature, presumably by allowing more 
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aromatic amino acids to enter the cell. This could be used to provide a further modulator 
on the ultra-strong promoters capable of staged outputs that we initially demonstrated.  
Finally, it would be very beneficial to sequence the final strains isolated through 
the ALE process. Through sequencing, we would be able to determine mechanisms for 
increased flux through the shikimate pathway which are common to all of them and 
unique to our final production strain. This could inform future work for the production of 
aromatic compounds in general, as well as generating targets for protein engineering to 
further increase muconic acid titers. It is of special interest that our final strain was able 
to gain a significant improvement from ARO1t relative to other ALE strains, suggesting 
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